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SUMMARY 
Tumor is a complex tissue composed of malignant and heterogeneous non-malignant cells. 
Tumor progression is determined by the dynamic interactions between these cells. Soluble 
factors secreted within the tumor microenvironment stimulate stromal cells and induce 
infiltration by inflammatory cells. High amounts of monocytes/macrophages, commonly found 
in various types of malignant cancer are associated with increased tumor cell extravasation 
and metastasis. A recent study reported that CCL2 recruits inflammatory monocytes to 
promote metastasis. Concerted action of chemokines and adhesion molecules (selectins) 
regulates the homing of leukocytes to target sites. However, the role of endogenous (non-
tumor derived) selectin ligands in metastasis was not characterized. 
To study the contribution of endogenous selectin ligands to metastasis, we used Fuc-TVII-/- 
mice which display defective selectin ligands. Reduced recruitment of monocytes to 
metastasizing tumor cells in Fuc-TVII-/- mice correlated with attenuated metastasis, 
suggesting the presence of endogenous selectin ligands on monocytes as a prerequisite for 
their capture at metastatic sites. Adoptive transfer of Fuc-TVII+ monocytes rescued 
metastasis, corroborating that monocyte recruitment is selectin ligand-dependent. Moreover, 
decreased CCL2 expression in Fuc-TVII deficient lung was linked to impaired monocyte 
recruitment, reduced tumor cell survival and attenuated metastasis. This study demonstrated 
that endogenous selectin ligands mediate the recruitment and activation of monocytes at the 
metastatic site and thereby facilitate metastasis. 
To delineate the molecular mechanism governing the effect of CCL2 on metastasis, we used 
different mouse models. Together with Monika Wolf, we demonstrated that CCR2 expression 
not only on monocytes, but in particular on the endothelium, is crucial for metastasis. Tumor 
cell-derived CCL2 induced vascular permeability and enabled efficient tumor cell 
extravasation via CCR2 signaling. The absence of CCR2 on the endothelium abolished 
tumor cell extravasation even in the presence of CCR2+ monocytes, highlighting that 
activation of CCR2 on the endothelium is a prerequisite for tumor cell migration. Collectively, 
our study identified a novel mechanism for CCL2-dependent metastasis. 
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ZUSAMMENFASSUNG 
Tumorgewebe ist ein komplexes Gebilde, das sich aus malignen und heterogenen nicht-
malignen Zellen zusammensetzt. Dynamische Wechselwirkungen zwischen diesen Zellen 
beeinflussen das Tumorwachstum. Lösliche Faktoren, sezerniert von der Tumor-
Mikroumgebung, stimulieren stromale Zellen und rufen eine Infiltration von 
Entzündungszellen hervor. Ein hoher Anteil an Monozyten/Makrophagen, wie er häufig bei 
verschiedensten Tumorarten vorkommt, korreliert mit einer erhöhten Extravasationsrate von 
Tumorzellen und folglich Metastasierung. Aktuelle Studien zeigen, dass die CCL2-abhängige 
Rekrutierung von Monozyten die Metastasierung fördert. Chemokine und Adhäsionsmoleküle 
(Selektine) regulieren auf abgestimmte Art und Weise die Einwanderung von Leukozyten in 
die Zielorgane. Die Rolle von endogenen (nicht von Tumorzellen stammenden) Selektin-
Liganden während der Metastasierung wurde jedoch bisher nicht charakterisiert. 
Um den Beitrag endogener Selektin-Liganden zur Metastasierung zu untersuchen, 
verwendeten wir Fuc-TVII-/- Mäuse, welche über nicht-funktionelle Selektin-Liganden 
verfügen. Verringerte Rekrutierung von Monozyten zu den metastasierenden Tumorzellen in 
Fuc-TVII-/- Mäusen korrelierte mit verringerter Metastasierung. Dies deutet darauf hin, dass 
die Anwesenheit von endogenen Selektin-Liganden auf der Oberfläche von Monozyten 
essentiell für das Anhaften an Metastasen-bildenden Stellen ist. Adoptiver Transfer von Fuc-
TVII+ Monozyten verhalf zu erfolgreicher Metastasierung und bestätigte somit die Selektin-
Ligand abhängige Rekrutierung von Monozyten. Weiterhin korrelierte verminderte CCL2-
Expression in Fuc-TVII-negativen Lungen mit beeinträchtigter Monozyten-Rekrutierung, 
reduzierter Überlebensrate der Tumorzellen und somit verringerter Metastasierung. Diese 
Studie zeigt somit, dass endogene Selektin-Liganden die Rekrutierung und Aktivierung von 
Monozyten vermitteln und dadurch erheblich zur Beschleunigung der Metastasierung 
beitragen. 
Um den molekularen Wirkmechanismus von CCL2 bei der Metastasierung zu verstehen, 
haben wir verschiedene Maus Modelle verwendet. Zusammen mit Monika Wolf haben wir 
demonstriert, dass CCR2-Expression nicht nur auf Monozyten sondern auch auf dem 
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Endothel für die Metastasierung entscheidend ist. Von Tumorzellen stammendes CCL2 
initiiert die Durchlässigkeit der Blutgefäße und ermöglicht dadurch eine effiziente 
Extravasierung der Tumorzellen durch CCR2-vermittelte Signalübertragung. Die 
Abwesenheit von CCR2 auf dem Endothel verhinderte die Extravasierung von Tumorzellen 
sogar in der Anwesenheit von CCR2+ Monozyten. Dies hebt die Aktivierung von CCR2 als 
Voraussetzung für die Extravasierung von Tumorzellen hervor. Zusammenfassend hat 
unsere Studie einen neuen Mechanismus der CCL2-abhängigen Metastasierung aufgedeckt. 
LIST OF ABBREVIATIONS 
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LIST OF ABBREVIATIONS 
BMDCs:  bone marrow-derived cells 
bFGF:  basic fibroblast growth factor 
CAFs:  cancer associated fibroblasts 
CCL2:  CC chemokine 2 
CCR2:  CC chemokine receptor 2 
CD:  cluster of differentiation 
CSF-1:  colony-stimulating factor-1 
EGF:  epidermal growth factor 
EC:  endothelial cell 
ECM:  extracellular matrix 
EMT:  epithelial-mesenchymal transition 
ERK:  extracellular signal regulated kinase 
ESL-1:  E-selectin ligand-1 
FAK:  focal adhesion kinase 
Fuc-T:  fucosyltransferase 
GLYCAM1:  glycosylation dependent cell adhesion molecule 1 
G-CSF:  granulocyte colony-stimulating factor 
GM-CSF:  granulocyte-macrophage colony-stimulating factor 
HEVs:  high endothelial venules 
ICAM:  intercellular adhesion molecule 
IFN:  interferon 
IL:  interleukin 
iNOS:  inducible nitric oxide synthase 
i.v.:  intravenous 
JAK2: Janus kinase 2 
LLC:  Lewis lung carcinoma 
M1:  pro-inflammatory macrophages, M1 phenotype 
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M2:  pro-tumor macrophages, M2 phenotype 
M-CSF:  macrophage colony-stimulating factor 
MAPK:  mitogen-activated protein kinase 
MC-38:  murine colon adenocarcinoma cells 
MDSCs:  myeloid-derived suppressor cells 
MHC:  major histocompatibility complex 
MMP:  matrix metalloproteinase 
N1:  pro-inflammatory neutrophils, N1 phenotype 
N2:  pro-tumor neutrophils, N2 phenotype 
NFκB:  nuclear factor kappa B 
NK:  natural killer cells 
PAF:  platelet-activating factor 
p.i.:  post injection 
PNAd:  peripheral lymph node addressin 
PSGL-1:  P-selectin glycoprotein ligand-1 
ROS:  reactive oxygen species 
SDF1:  stromal cell-derived factor-1 
sLex:  sialyl-Lewisx 
STAT:  signal transducers and activators of transcription 
TAMs:  tumor-associated macrophages 
TANs:  tumor-associated neutrophils 
TNFα:  tumor necrosis factor alpha 
TGF:  transforming growth factor 
VEGF:  vascular endothelial growth factor 
VEGFR: vascular endothelial growth factor receptor 
VCAM:  vascular cell adhesion molecule 
uPAR:  urokinase plaminogen activator receptor  
uPA:  urokinase plaminogen activator 
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INTRODUCTION 
1. Metastasis 
Metastasis is a multistep process that involves the spread of tumor cells from the primary 
tumor to distant organs. It comprises a complex set of events including increased 
invasiveness, intravasation into circulatory system, survival, adhesion, extravasation and 
colonization.1-4 Earlier hypothesis considered metastatic dissemination as the final step of 
cancer progression. However, recent findings identified cancer spread as an early event 
suggesting that metastatic abilities of cells can be acquired outside the primary lesion and do 
not necessarily develop first with large tumors.5 Thus, disseminated tumor cells might 
develop parallel to the primary tumor and display different genetically and phenotypically 
alterations due to the selection pressure at sites distant from the primary tumor.6-8 Upon 
curative resection of the primary tumor metastasis become the major cause for cancer-
related death and prompted substantial interest of researchers into cellular and molecular 
mechanisms governing metastasis.9 
 
1.1. Metastatic cells in circulation 
Despite continual release of millions of tumor cells into the circulation, only a few cells 
leaving the primary tumor can successfully establish distant metastases.10,11 The majority of 
circulating tumor cells in the blood stream are rapidly eliminated.9,12 After intravenous 
injection of radiolabelled B16 melanoma cells only 0.1 % of cells were viable 24 hours later 
and less than 0.01 % of cells were able to establish experimental lung metastasis.10 Still, the 
question of how disseminating tumor cells survive and proliferate at a distant site is not yet 
answered. 
When patients are diagnosed with cancer, they usually already have tumor cells in the 
circulation. During entry into the bloodstream, disseminating tumor cells interact with blood 
components including platelets and leukocytes thereby forming so called “tumor cell 
emboli”.13-15 Clinical and experimental studies revealed that tissue factor expressed by tumor 
cells triggers thrombin formation through the interaction with coagulation factors VII and X 
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(FVII and FX).16,17 Indeed, thrombotic events are frequently present in cancer patients and an 
increase of procoagulants in blood is a prognostic tool for a poor outcome.18,19 Fibrinogen 
deficiency in mice reduced metastasis of B16 melanoma and Lewis lung carcinoma cells to 
the lung indicating the importance of fibrinogen in sustained adhesion and survival of tumor 
cells in the lung vasculature.20 In addition, defective platelet activation mediated by the 
absence of platelet receptors (e.g GPVI, GPIβ, PAR4, Gαq) diminished metastasis in several 
mice models.21-24 Likewise, inhibition of integrins on platelets, tumor, or endothelial cells, 
leads to reduced metastatic potential demonstrating a crucial role of integrins in tumor cell-
mediated interactions with platelets, leukocytes and endothelial cells in metastasis.25,26 
Tumor cell emboli protect tumor cells from immune surveillance and ensure a prolonged 
tumor cell survival within the bloodstream.21,27 Co-incubation of tumor cells with platelets 
prevented tumor cell lysis by natural killer (NK) cells in vitro confirming the fact that NK cell-
mediated elimination of target cells requires direct cell-cell contact.27 Platelet-derived 
transforming growth factor beta (TGFβ) impaired NK cell reactivity in vitro, demonstrated by 
reduced granule mobilization, cytotoxicity and interferon γ (IFNγ) production.28 Further, mice 
depleted with NK cells and inoculated with tumor cells showed no differences in metastasis 
between platelet depleted and control groups. Thus, platelets promote metastatic spread by 
forming a physical barrier and protecting tumor cells from NK-mediated clearance. In 
addition, platelets mediate tumor cell adhesion to the endothelium and assist in tumor cell 
extravasation.20,29 A recent study revealed a novel role for platelets in cancer dissemination.30 
Platelets secreted TGFβ induced epithelial-mesenchymal-like transition (EMT) in tumor cells 
through direct tumor-cell-platelet contact. Consequently, tumor cells became more invasive 
and highly metastatic.30 This study indicates that platelets do not only cooperate in tumor cell 
survival and transmigration but can also reprogram tumor cells through direct interactions. 
Although the contribution of leukocytes to thrombus formation is well accepted, the molecular 
mechanisms underlying this process are only beginning to emerge (discussed later).31-34 
Activated platelets and locally stimulated endothelial cells secrete chemokines that recruit 
inflammatory leukocytes to the tumor site via chemokine signaling.35 The initial association of 
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tumor cells with leukocytes, platelets and endothelial cells is mediated by selectins.36,37 
Selectin deficiency or inhibition of selectins attenuated metastasis in several mice 
models.33,38,39 Selectin-dependent activation and aggregation of platelets imply a complex 
interplay between tumor cells, platelets, leukocytes and endothelial cells during circulation 
and extravasation.31,34 
 
1.2. Tumor cell extravasation 
Tumor cells seed to multiple organs, but only in a few organs can the metastatic tumor grow 
and develop metastases. The establishment of a permissive tumor microenvironment is 
required for the successful colonization.40 The infiltration barriers as well as the composition 
of the microenvironment are tissue-dependent and might explain the metastatic tropism of 
some types of cancer.4,12 Endothelial cells in the vasculature of different organs express 
different cell adhesion molecules.41,42 Therefore, tumor cells with corresponding counterparts 
can utilize these specific receptor-ligand interactions to adhere to specific tissue.3 For 
example, breast cancer cells could specifically adhere to the lung vasculature and increase 
lung metastasis by over-expressing metadherin.43 In addition, different vascular structures in 
organs can influence the extravasation abilities of tumor cells. Organs like bone marrow and 
liver, with characteristic fenestrated capillaries, are readily invaded by tumor cells when 
compared to lung or brain. In the latter organs cells need to migrate through the tight layer of 
endothelial cells surrounded by a basement membrane.3,44,45 Thus, tumor cells require 
specific mediators that facilitate the process of extravasation in these organs.46,47 After 
extravasation, tumor cells can grow and establish a metastatic foci only if the 
microenvironment of the target site provides an adequate supply of growth factors and stimuli 
required for tumor cell proliferation.12,48,49 
Since detection and treatment of micro/macro-metastasis remains challenging, agents that 
can prevent early steps of metastasis are in demand. Targeting tumor cell emboli formation 
and extravasation represent an interesting and feasible mechanism to intervene in the 
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metastatic process. Thus, understanding the mechanisms by which selectins potentiate 
metastasis is the prerequisite for a promising anti-cancer therapy. 
 
2. Selectins 
Selectins belong to a family of vascular cell adhesion molecules. The structure of selectins 
encompasses an intracellular domain that interacts with the cytoskeleton, a transmembrane 
domain and an extracellular domain which is organized in two or nine consensus repeats, an 
epidermal growth factor-like (EGF) domain and a C-type lectin domain.50,51 There are three 
members of selectins: P-selectin, E-selectin and L-selectin. L-selectin is constitutively 
expressed on all myeloid cells, most lymphocytes and on a subset of natural killer cells.52 P-
selectin is stored in α-granules in unstimulated platelets and in Weibel-Palade bodies of 
resting endothelial cells. It is rapidly translocated to the cell surface upon cell stimulation.53,54 
In contrast, E-selectin is synthesized de novo in response to inflammatory stimuli and its 
expression is restricted to endothelial cells. In some tissues such as skin and functional 
microdomains in the bone marrow, E-selectin is expressed constitutively on endothelial 
cells.55,56 
 
2.1. Physiological role of selectins 
Physiological functions of selectins are well described for processes like inflammation, the 
immune response, homeostasis and wound healing. The best studied role of selectins 
includes leukocyte trafficking.52,57 Mature lymphocytes permanently recirculate from the blood 
into secondary lymphoid organs to provide an effective immune response. L-selectin 
mediates the extravasation of lymphocytes from the blood system and their homing to high 
endothelial venules (HEVs) in lymph nodes and to Peyer`s patches (lymphoid tissue in the 
gut).57 Loss of L-selectin prevents lymphocyte homing and results in diminished immune 
response.58 
Selectins also regulate the recruitment of leukocytes to sites of acute inflammation or injury. 
In blood, circulating leukocytes are under conditions of high shear stress. Under normal 
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conditions, endothelial cells and circulating leukocytes are not adhesive.59 In response to 
inflammatory stimuli, endothelial cells express P- and E-selectin that together with L-selectin 
on leukocytes mediate the initial capture and rolling of leukocytes and platelets along the 
endothelium.59-61 Rolling involves rapid formation of bonds at the leading edge of the 
circulating cells with the endothelium and rapid bond dissociation at the trailing edge.57 
Synergistic effects of multiple low-affinity selectin ligands lead to high avidity which enables 
selectins to cause circulating leukocytes to begin rolling.57,62,63 This initial contact of 
leukocytes with endothelium provides sufficient time for the cells to be exposed to activating 
stimuli present on the vessel wall or released locally and to transmit the activating signals 
through adjacent signaling molecule receptors (e.g. G-protein-coupled receptors).64 
Chemokines, cytokines or platelet-activating factor (PAF) induce leukocyte activation and 
trigger firm attachment to the endothelium which is mediated by binding of leukocyte 
integrins to intercellular adhesion molecules (ICAM) and vascular cell adhesion molecules 
(VCAMs) present on endothelial cells. Changes in shape promote activated leukocytes to 
migrate through the endothelial cell junctions, a process that involves interaction with 
endothelial junction proteins.59 Platelet-derived P-selectin assists the efficient interaction of 
leukocytes with the endothelium by stimulating the activation of these cells.65 The multistep 
cascade of leukocyte recruitment is demonstrated in Figure 1. 
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Figure 1. Leukocyte extravasation cascade. 
Extravasation of leukocytes is initiated by the activation of endothelial cells, which expose E-and P-
selectin and signaling molecules on the cell surface (1). The cascade is divided into several steps 
including capture (2), rolling (3), signaling activation (4) adhesion and arrest (5) followed by 
transmigration of leukocytes (6). Selectins mediate initial contact with the endothelium whereas firm 
adhesion of leukocytes is integrin dependent. After adhesion and crawling the cells finally transmigrate 
into the parenchyma. These events occur in a coordinated temporal fashion, ensuring spatial and 
temporal recruitment of leukocytes to the inflamed site. PMN: polymorphonuclear cells (McIntyre et al., 
2003). 
 
Interference with adhesive interactions at either the rolling, firm adhesion or transmigration 
steps decreased leukocyte migration and attenuates innate and adaptive immune responses 
during inflammation.57,66 Interestingly, not all organs depend on a selectin-mediated adhesion 
cascade of leukocytes. For example, neutrophils were able to infiltrate lung and liver in P-
selectin or E-selectin/P-selectin deficient mice. Whereas neutrophil recruitment to skin, 
skeletal muscle, heart and kidney, was dependent on selectin expression.51,67,68 
 
Another prominent feature of selectins is their involvement in thrombosis. P-selectin 
expressed on activated platelets interacts with ligands on leukocytes and facilitates thrombi 
formation together with leukocytes.69 Furthermore, P-selectin potentiates coagulation through 
the generation of leukocyte-derived microparticles.70 Microparticles carry tissue factor that 
acts as key inducer of the extrinsic coagulation cascade.71 P-selectin may also modulate 
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fibrin deposition and the resulting thrombus size.70 The absence of P-selectin prolongs the 
bleeding time after injury confirming the role of P-selectin in thrombus formation.72 
Various inflammatory stimuli like tumor necrosis factor-α (TNFα), interleukin-1β (IL1β) and 
histamine may stimulate the expression of L- and E-selectin as well as the degranulation of 
P-selectin.52,73 Resting upon different regulatory mechanisms selectin expression and 
exposure on the cell surface is tightly controlled during homeostasis and ensures spatial and 
temporal recruitment of leukocytes during inflammation. 
 
2.2. Selectin ligands 
Selectins exert their functions through interactions with selectin ligands. Selectin ligands bind 
to the C-type lectin domain of selectins through specific carbohydrate determinants in a 
calcium-dependent manner. The minimal recognition motif for all selectins are the 
tetrasaccharides (Figure 2) sialyl-Lewisx (sLex) and its isomer sialyl-Lewisa (sLea).74,75 sLex is 
sequentially synthesized by N-acetyl-glucosaminyltransferase, β1,4-galactosyltransferase, 
α2,3-sialyltransferase and α1,3-fucosyltransferase VII enzymes. N-acetyl-
glucosaminyltransferase initiates synthesis of the sLex structure on poly-N-
acetyllactosamines found on core O- and N-linked glycans displayed on proteins.52,57,76 
 
Figure 2. Structure of a sialyl-Lewis
x
 and sialyl-Lewis
a 
(adapted from Reis at al. 2010). 
Carbohydrates with no sialic acid or fucose are poor ligands for selectins.52,77 Additional post-
translational modifications (e.g. glycosylation, sulfation) either on the sLex  moiety or on the 
protein backbone potentiate selectin recognition of the ligand. Since all selectins share the 
same recognition motif, their selectivity depends on specific combinations of saccharides 
presented by the polypeptide backbone resulting in so called “clustered saccharide 
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patches”.77 Clustering of selectin ligands enhances the binding avidity of selectins and 
enables rapid contact formation. Highly glycosylated proteins facilitate the presentation of 
several selectin ligands in clusters. To date, the best characterized selectin ligand is P-
selectin glycoprotein ligand-1 (PSGL-1).78 PSGL-1 is expressed on leukocytes and is 
recognized by all three selectins79-81, whereas the affinity for P- and L-selectin is increased by 
sulfation of tyrosines Tyr48 and Tyr51 near the N-terminus of the molecule.82 Another 
selectin ligand, Glycosylation-dependent cell adhesion molecule-1 (GLYCAM1), requires 
sulfation of the carbohydrate chain for L-selectin recognition.83 
Glycoproteins like GLYCAM1, endoglycan, podocalyxin and CD34 are highly expressed in 
HEVs. They belong to the so called peripheral lymph node addressin (PNAd) complex and 
regulate lymphocyte homing to the lymph nodes.57 
Glycoproteins that mediate infiltration of leukocytes to sites of inflammation include PSGL-1, 
CD44, CD24 and E-selectin ligand-1 (ESL-1).84-86 Leukocytes express an extensive 
repertoire of these glycoproteins on their surface. L-selectin on human neutrophils also 
carries carbohydrate determinants that are recognized by E-selectin. In contrast, mouse L-
selectin does not bind to E-selectin indicating that selectin ligands in different species might 
have altered posttranslational modifications or are attached to different protein scaffolds.87 It 
has been shown that PSGL-1 is responsible for initial leukocyte capture. ESL-1 converts the 
initial tethering, mediated by PSGL-1, into steady, slow rolling, whereas CD44 regulates the 
velocity of the slowly rolling leukocytes.86 These data demonstrate how different selectin 
ligands cooperate together in a distinct and dynamic mode in order to promote leukocyte-
endothelial interactions resulting in the extravasation of leukocytes to the inflammatory site. 
The binding specificity of the same selectin ligand to its receptor might vary, depending on 
the cell-specific glycosylation pattern. CD44 expressed on hematopoietic progenitor cells 
was identified as a physiological L-and E-selectin ligand.85,88,89 In contrast, T-cell-derived 
CD44 binds preferentially to hyaluronate and mediates T-cell extravasation to the site of 
inflammation.90 The binding partner of endothelial-derived CD44 has not yet been identified.50 
Alternatively, P- and L-selectin interact with sulfated ligands like heparin, heparin sulfate, 
INTRODUCTION 
21 
fucoidan and sulfated glycolipids.77,91 Analysis of cell-specific expression of selectin ligands 
and their affinities for selectins could increase understanding of distinct functions. 
Carcinoma cells display on their surfaces mucins with altered carbohydrate antigens.92,93 
Mucins are large proteins that bear many oligosaccharides packed closely together.94 High 
expression of sLex and sLea is a major alteration on cancer mucins and correlates with tumor 
progression and metastasis.95 Tumor associated sLex and sLea structures are major selectin 
ligands on cancer cells. Other tumor bearing selectin ligands like ESL-1, PSGL-1, death 
receptor 3, CD44 and CD24 have been reported. However, the biological relevance of these 
selectin ligands remains to be elucidated. 
Most selectin counterparts have been identified using in vitro affinity purification 
techniques.89,96 Binding affinity to a specific selectin type has been evaluated in vitro under 
static conditions rather than under fluid flow conditions which correspond more accurately to 
the natural processes found in the vasculature.97 Only a few putative selectin ligands have 
been shown in animal models to mediate physiologically relevant interactions with selectins. 
Since only a few inhibitory antibodies are available, due to the poor immunogenicity of 
glycosylated epitopes, it remains challenging to prove the biological interaction of selectin 
ligands with their counterparts. Gene disruption is a commonly used strategy to ascertain the 
in vivo function of major selectin ligands.98 
 
2.3. Selectin-selectin ligand-mediated signaling 
Many studies have revealed different signaling pathways that are involved in selectin-
mediated leukocyte extravasation. Selectin-selectin ligand interactions induce signaling in 
both the selectin-expressing and the ligand-expressing cells.99-102 Selectin-mediated rolling of 
leukocytes stimulates a transient increase of Ca2+ in endothelial cells that is required for 
transit of cells across the endothelial cell barrier.100 Focal adhesion kinase (FAK) has been 
activated in response to selectin binding of lymphocytes to the endothelial surface.103 FAK 
promotes vascular permeability and up-regulation of endothelial adhesion molecules. 
Adhesion of myeloid cells to platelets via P-selectin-PSGL-1 interactions induces 
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translational amplification of urokinase plaminogen activator receptor (uPAR) in myeloid 
cells.104 uPAR is an important protease receptor which regulates cell adhesion and migration 
during extravasation by coordinating extracellular matrix proteolysis and activating 
intracellular signaling pathways that support actin cytoskeleton reorganization.105 P-selectin 
binding to human monocytes induces nuclear translocation of NF-kB that results in increased 
secretion of cytokines including TNF-alpha and CCL2 in vitro.60 This observation may explain 
the contribution of selectins to local activation of cells during inflammation. Furthermore, E-
selectin binding to leukocytes induces endothelial signal transduction and activation of Ras, 
Raf and extracellular signal-regulated kinases (ERK1/2) that in turn modulate the gene 
expression of adhesion molecules.101 In contrast, L- and E-selectin-mediated leukocyte 
tethering and rolling on endothelial cells led to expression of integrins on leukocytes through 
the activation of p38, SYK and Src kinase pathways.106-109 Engagement of different pathways 
suggests complex mechanisms for selectins contribution to cell-cell interactions. In addition, 
selectin-mediated interactions not only tether leukocytes, but also transmit outside-in signals 
that trigger morphological changes and alter gene expression. 
 
2.4. Role of selectins in pathogenesis 
Due to the involvement of selectins in various physiological situations (discussed above) 
aberrant selectin function is associated with many pathologies. Loss of individual or several 
selectins results in impaired leukocyte trafficking and causes increased susceptibility to 
opportunistic bacterial infections and toxic agents.58,110 In contrast, each member of the 
selectin family (L-, P- and E-selectin) has been shown to facilitate acute inflammation and 
tissue damage in different disease models by virtue of enhanced leukocyte recruitment to the 
site of inflammation.58,111,112 In patients with vascular disease and Crohn`s disease, soluble 
forms of P- and E-selectins were found in serum where they function as risk factors.113 P-
selectin neutralization abolished leukocyte infiltration and markedly decreased permeability 
of the small intestine in mice treated with endotoxin.112 Inhibition of P and E-selectin 
protected ischemia/reperfusion-induced renal failure and showed reduced coagulation and 
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mortality in an experimental septic shock model.111,114 Chronic inflammation is also 
associated with the ability of selectins to trigger thrombi formation. Studies of selectins in 
animal models revealed their involvement in the pathogenesis of atherosclerosis and 
arthritis. P-selectin expression on platelets facilitates platelet-monocyte aggregation and 
interaction of the aggregates within atherosclerotic lesions.65 This selectin-mediated 
aggregation stimulates the local secretion of proinflammatory factors and strong infiltration of 
monocytes. Lack of P-selectin reduces platelet-induced monocyte recruitment on the 
endothelium and results in delayed onset of atherosclerosis.65 The absence of L-and E-
selectin also attenuated the progression of atherosclerotic lesions.115-117 Sickle cell anemia is 
a disease in which red blood cells have an abnormal form accompanied by short life time, 
high stiffness and stickiness. P-selectin on endothelial cells accelerates sickle cell anemia by 
interacting with sickled erythrocytes.118 Interestingly, vascular occlusion induced by sickle cell 
binding to firmly attached leukocytes on endothelium was absent in mice deficient both in P-
and E-selectins.119 Selectins are also involved in the coagulation abnormalities often 
observed in cancer patients.120 Cancer patients are at high risk for thromboembolic events, a 
phenomenon that is known as Trousseau syndrome. Adenocarcinomas display and secrete 
high levels of mucins that can be recognized by selectins. Intravenous injection of purified 
carcinoma mucins triggered rapid platelet-rich microthrombi formation.31 Deficiency either in 
P- or L-selectin reduced mucin-mediated platelet aggregation, indicating the importance of 
selectins in thrombotic events accompanying cancer progression.31 
Collectively, these data indicate the role of selectins in regulatory processes of inflammation 
and cancer progression. Methods to block selectin-mediated interactions provide an efficient 
tool to prevent these events. 
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2.5. Fucosyltransferases 
Fucosyltransferases are enzymes that catalyze the final step in the biosynthesis of selectin 
ligands.84 To date, 11 fucosyltransferases (Fuc-Ts) have been identified. All 11 enzymes 
catalyze the transfer of fucose from GDP-fucose to various oligosaccharide acceptors. 
Depending on the linkage of fucose to the acceptor molecule, Fuc-Ts are divided into four 
groups. Fuc-TI and Fuc-TII synthesize α1-2 fucose. Fuc-TIII, Fuc-TIV, Fuc-TV, Fuc-TVI, Fuc-
TVII and Fuc-TIX are involved in the synthesis of α1-3/α1-4 fucose. Fuc-TVIII synthesizes 
α1-6 fucose. Fuc-TX and Fuc-TXI have been recently identified and their specific activity 
remains to be confirmed.121 Two of these enzymes, Fuc-TIV and Fuc-TVII, are expressed in 
leukocytes and control the synthesis of selectin ligand sLex by transferring the fucose in α1,3-
linkage to GlcNAc on the precursor moiety.122 The importance of Fuc-TIV and Fuc-TVII in 
generation of selectin ligands has been identified in mice with targeted deletions in these 
genes. Mice deficient in the Fuc-TVII gene have a strong impairment in lymphocyte homing 
and in neutrophil infiltration into inflamed peritoneum.123 The targeted loss of fucosylation 
leads to a marked reduction of selectin ligand activity on leukocytes and HEVs, 
demonstrating a central and essential role for Fuc-TVII in selectin ligand biosynthesis. 
Leukocytosis observed in Fuc-TVII deficient mice is mainly caused by increased neutrophil 
numbers (7-fold).123 Elevated leukocyte numbers were also observed in P- and E-selectin 
double deficient mice.110,124,125 Similar to Fuc-TVII deficient mice, patients with leukocyte 
adhesion deficiency type II (LADII), who carry mutations in the Fuc-TVII gene, showed 
impaired leukocyte interactions with the endothelium. As a result impaired wound healing 
and increased propensity to infection is commonly observed in these patients.126,127 Taken 
together, this shows that the selectin-selectin ligand axis is required to maintain homeostasis 
of myeloid lineage leukocytes under normal physiological conditions.84 
In contrast, the lack of Fuc-TIV has minimal effect on leukocyte trafficking. However, the 
retained selectin ligand activity in Fuc-TVII deficient neutrophils was abolished in mice 
deficient in both fucosyltransferases Fuc-TVII and Fuc-TIV. The residual lymphocyte homing 
activity to HEVs in Fuc-TVII deficient mice was strongly reduced in mice with the double 
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mutation.128 The collaborative effect of Fuc-TIV and Fuc-TVII shows that both enzymes 
control the generation of selectin ligands, though Fuc-TVII has a dominating role over Fuc-
TIV.128 In vitro studies with synthetic polylactosamine precursors revealed distinct site-
directed preferences between the Fuc-TVII and Fuc-TIV enzymes. Fuc-TIV preferentially 
fucosylates “inner“, whereas Fuc-TVII prefers “distal” lactoseamine units of precursors. 
These observations suggest that both enzymes contribute to selectin ligand synthesis in a 
site-specific manner.129 Additionally, in vivo studies showed that Fuc-TIV preferentially 
generated sLex-like epitopes on glycolipids, which might explain why Fuc-TIV is less 
important in protein-based selectin ligand biosynthesis than Fuc-TVII.130 It is likely that other 
ligands may still bind to selectins even if both fucosyltransferases Fuc-TVII and Fuc-TIV are 
missing.131 However, the structure and the biological relevance of these ligands remain to be 
determined. 
Interestingly, a recent study revealed that in human gastrointestinal tissues, as well as in 
colon cancer, Fuc-TVI is a key regulator of sLex biosynthesis, whereas the functions of Fuc-
TIV and Fuc-TVII are negligible. This indicates that contributions from different 
fucosyltransferases to the biosynthesis of sLex are cell/tissue specific.132 
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2.6. Selectin-selectin ligand axis in tumor progression 
During the hematogenous phase of metastasis, circulating cancer cells undergo a range of 
cell-cell interactions which determine tumor cell survival, adhesion and extravasation. 
 
Figure 3. Potential interactions of a tumor cell with selectins. 
Entering the blood stream, tumor cells interact with blood elements (cells and soluble factors) and the 
vascular endothelium. These interactions are determinants for metastasis. The schematic model 
depicts all possible interactions of carcinoma cell mucins with selectins present on blood constituents 
(platelets, leukocytes and endothelial cells) as well as selectin-mediated natural crosstalk between the 
host cells (adapted from Borsig 2004). 
 
Cancer cells often express a unique repertoire of glycans.133 For instance, malignant cells, 
especially adenocarcinomas, display aberrant forms and amounts of mucins as a 
consequence of deregulated enzymes that modify them.93 
Clinical observations and experimental studies provide accumulating evidence for the role of 
a selectin-selectin ligand axis in cancer progression.36,37 The majority of cancer cells, 
including melanomas, colon, gastric, breast and lung carcinomas display high levels of the 
selectin ligands sLex and sLea, and this is associated with progression and poor prognosis.134 
Numerous studies suggest that selectin-mediated processes might be exploited by the 
metastasizing tumor cells including the pro-coagulant activity, recruitment of leukocytes and 
stimulation of inflammatory pathways.91 Mice deficient in one or more selectins show reduced 
metastasis and therefore confirm the involvement of all three selectin members in 
cancer.32,33,135,136 
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2.6.1. P-selectin in tumor progression 
Cancer cell-mediated activation and binding of platelets is an important step in cancer 
progression.13-15 The ability of tumor cells to form “tumor emboli” correlates with increased 
metastasis.14,21,137 Attenuated metastasis and higher survival rate have been observed in 
mice with induced thrombocytopenia as well as in platelet-deficient mice.21,22 How do 
platelets facilitate metastasis? Platelets aggregate around tumor cells and protect them from 
the immune system.21,27 Animal models provided evidence that thrombi formation is primarily 
P-selectin dependent.39,138 P-selectin deficiency reduces tumor cell-platelet interactions 
thereby causing a decreased tumor cell seeding to the lung.39,138 Enzymatic removal of tumor 
cell mucins prior to intravenous injection resulted in decreased metastasis, indicating that P-
selectin-mediated binding to mucins is essential for tumor cell-platelet aggregation.138 The 
contribution of endothelial P-selectin to tumor cell-microvasculature interactions has been 
elucidated by the use of bone marrow reconstitution experiments in P-selectin-deficient 
mice.135 Tumor cells have been shown to interact with postcapillary venules in a P-selectin-
dependent manner, indicating that both, platelet and endothelial P-selectins, enhance 
metastasis.135 Moreover, growth factors and cytokines released by activated platelets might 
supply tumor cells with critical factors to ensure their survival during circulation.13-15 In 
addition, tumor microemboli interact with endothelial cells and thereby contribute to the arrest 
of tumor cells and their extravasation.25,35,39 
Heparin, a highly sulfated glycosaminoglycan, prevented metastasis and improved patient 
survival.139,140 Beyond its anticoagulant activity, heparin has been shown to attenuate 
metastasis in different tumor models due to its ability to block the binding of P-selectin to 
tumor cell glycans thereby preventing tumor cell emboli formation.135,138 P- and L-selectin-
mediated microthrombi formation was also associated with high thromboembolic events 
observed in patients with Trousseau syndrome that suffer from advanced cancer.31 In 
addition, L-selectin-dependent interactions with mucins led to cathepsin G secretion in 
neutrophils.34 Released cathepsin G in turn, activated platelets and triggered P-selectin 
expression.34 Thus, tumor cells employ both, platelets and leukocytes in a selectin-
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dependent manner and benefit from the reciprocal signaling of these cells, promoting thrombi 
formation and eventually metastasis. 
 
2.6.2. L-selectin in tumor progression 
High leukocyte infiltration in tumors has been associated with tumor progression and poor 
prognosis.141-143 Inflammatory stimuli secreted by the tumor cell itself or by the surrounding 
microenvironment recruit leukocytes to primary tumor sites or metastatic lesions. Initial 
leukocyte response to tumors resembles, in general, the inflammatory response during 
infection or wound healing.12,141,144 However, the impact of interactions between tumor and 
host cells within the bloodstream has been less explored. Recently, the interplay between 
tumor cells, platelets and leukocytes has been shown to stimulate an inflammatory 
microenvironment that activates the adjacent endothelial cells and triggers the recruitment of 
L-selectin-expressing leukocytes.35 The absence of L-selectin resulted in attenuation of 
metastasis, implicating its role in this process.33 Reduced recruitment of CD11b+ leukocytes 
to tumor sites correlated with decreased tumor cell survival in the lung, confirming that L-
selectin mediates leukocyte recruitment to metastatic sites.33 The absence of L-selectin has 
further reduced metastasis in P-selectin deficient mice, implicating a synergistic action of P- 
and L-selectin in thrombi formation and metastasis, respectively.32 L-selectin expressing 
leukocytes might also mediate the interaction of tumor cell emboli with L-selectin ligand 
expressing endothelial cells.32 These findings indicate the ability of leukocytes to promote 
metastasis either by supporting tumor emboli formation or by tumor cell-endothelial 
interaction in an L-selectin dependent manner. Further evidence suggests that leukocytes 
assist tumor cells in breaching the endothelial barrier and might directly increase the 
migration of cancer cells.145 The contribution of L-selectin-mediated interaction has been 
recently delineated (L.Borsig manuscript in preparation). 
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2.6.3. E-selectin in tumor progression 
The local up-regulation of E-selectin in the vasculature in response to trapped tumor cell 
emboli has been observed in different mice models and with different tumor cell lines.33,35,146 
These observations imply that tumor cells are able to activate endothelial cells within the 
metastatic microenvironment and may exploit E-selectin interactions for successful 
colonization. Indeed, inhibition of E-selectin induced either by antisense oligonucleotides or 
neutralizing antibodies, reduces tumor cell adhesion and metastasis in several experimental 
metastasis models.147-149 Interestingly, LS180 human colon carcinoma cells managed to 
metastasize and colonize the lung even in the absence of E-selectin, suggesting that 
different tumor cells apply different mechanisms for metastasis.150 In addition, the metastatic 
microenvironment and the tissue-specific features of the target organ influence metastatic 
spread.151 Over-expression of E-selectin in the liver of a transgenic mouse redirected tumor 
cell metastasis to this organ, clearly indicating the contribution of E-selectin to this 
process.152 Endothelial E-selectin mediates tumor cell arrest by a direct interaction with E-
selectin ligands displayed on tumor cells.147,153 Expression of E-selectin ligands on tumor 
cells correlates directly with their enhanced adhesion to endothelial cells in vitro.95,154 
Accordingly, binding of E-selectin-ligand with a soluble form of E-selectin or with a peptide 
mimicking E-selectin ligand inhibits lung colonization by tumor cells.38,155 However, tumor 
cells need first to activate the endothelial cells to trigger E-selectin interactions. In this 
context, tumor cells have been shown to co-opt inflammatory pathways followed by 
increased levels of cytokines within the metastatic microenvironment that ultimately promote 
E-selectin activation.146 The importance of E-selectin in metastasis is also evident in 
regulation of cancer cell diapedesis through the endothelial cell layers.156,157 The molecular 
mechanism of E-selectin-mediated tumor cell extravasation involves the activation of ERK 
and p38 mitogen-activated protein kinase (MAPK). In turn, activated kinases initiate a 
cascade of events leading to stress fibre formation and increased vascular permeability, 
thereby enabling the extravasation of adherent tumor cells.157 Further, E-selectin up-
regulation has been reported to initiate the homing of metastatic cancer cells to specific foci 
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in the lungs in a spontaneous breast metastasis model.158 Cancer cell homing to lungs was 
abolished in E-selectin deficient mice, demonstrating the contribution of E-selectin to 
metastatic niche formation.158 Thus, E-selectin not only promotes metastasis by guiding 
tumor cells and facilitating their adhesion to the vasculature, but it also transmits outside-in 
signals that support tumor cell extravasation. 
 
2.6.4. Role of selectin ligands in tumor progression 
Previous data showed strong evidence that P-, L- and E-selectin engagement with tumor cell 
selectin ligands facilitates metastasis. However, the role of endogenous selectin ligands 
expressed on host cells in metastasis formation has not yet been elucidated. It has been 
shown that neutrophils are able to roll on neutrophils already arrested on the 
endothelium.159,160 The process of secondary capture is mediated exclusively by L-selectin 
and provides permanent leukocyte recruitment during inflammation. The phenomenon of 
secondary capture has been observed in cytokine-stimulated arterial vessels and on 
atherosclerotic lesions in the aorta.161 L-selectin inhibition prevented secondary capture and 
decreased the flux of rolling leukocytes in arterial vessels.161 These data clearly indicate the 
contribution of host-derived selectin ligands to the inflammatory response. However, the 
process of secondary capture in metastasis has not been studied. Furthermore, endogenous 
selectin ligands might be important in tumor emboli formation, based on selectin-mediated 
reciprocal signaling between platelets and leukocytes observed in a model of Trousseau 
syndrome.34 The capacity of endogenous selectin ligands to promote metastasis has been 
reported recently.33 Endogenous L-selectin ligands were up-regulated at the sites of 
intravascular tumor cell arrest in the lung of wild type mice. In contrast, no L-selectin ligands 
were detected around tumor cells in Fuc-TVII-/- mice. The lack of endogenous selectin 
ligands correlated with reduced lung metastasis in Fuc-TVII-/- mice.33 Together, these data 
provide evidence that metastasis depends not only on direct selectin binding to tumor cells 
carrying selectin ligands, but also on the recognition of selectin ligands on host cells. These 
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interactions might activate intrinsic signaling cascades leading to amplification of the 
inflammatory response.35 
 
3. Tumor microenvironment 
Tumor is a complex tissue composed of malignant cells and multiple stromal cell types such 
as fibroblasts, epithelial cells, endothelial cells and infiltrating leukocytes. Initially, it was 
proposed that tumor cells alone drive carcinogenesis caused by neoplastic transformation. 
During the last decades, the supportive role of the tumor microenvironment became obvious. 
Current experimental and clinical evidence confirm that the interplay between tumor and non-
malignant cells is crucial for tumor development at both, primary and metastatic sites. 
 
3.1. Primary tumor microenvironment: composition and function 
Tumor cells stimulate their microenvironment by direct cell-cell interactions and/or by 
secretion of soluble mediators, which allow them to educate the adjacent stromal cells. 
Stromal cells may originate from proliferated pre-existing stromal cells (e.g. epithelial cells, 
fibroblasts, endothelial cells), from in situ differentiated local stem cells or by recruitment of 
bone marrow-derived progenitor cells.12,162 Upon stimulation, these cells secrete many 
factors that affect different aspects of tumor development, including tumor growth, 
angiogenesis, immunosuppression, invasiveness and metastasis. 
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Figure 4. Composition of the primary tumor. 
Primary tumor consists of cancer cells embedded in a complex network of stromal (left panel) and 
infiltrating (right panel) host cells. Dynamic interactions between these cells profoundly enhance tumor 
progression. The crosstalk supports tumor growth, angiogenesis, extracellular matrix degradation and 
metastasis through direct cell-cell contact and the production of a plethora of factors (e.g. cytokines, 
chemokines, growth factors and matrix-degrading enzymes, etc.). BMDC: bone marrow-derived cells. 
MDSC: myeloid-derived suppressor cells (Joyce et al. 2009). 
 
3.1.1 Fibroblastic cells in tumor microenvironment 
In solid tumors, cancer associated fibroblasts (CAFs) represent the major population of the 
stromal microenvironment.163 There are suggestions that during tumor initiation CAF-derived 
proteases might support tumor growth by loosening the epithelial architecture and by 
degrading the growth suppression factors secreted by surrounding cells.164 Indeed, CAF-
derived proteases have been shown to release latent angiogenic factors like vascular 
endothelial growth factor (VEGF) or transforming growth factor β (TGFβ) sequestered in the 
ECM that in turn facilitated neovascularization and thereby promote tumor growth. CAFs 
might also secrete paracrine factors like VEGF or interleukin-8 that drive tumor 
angiogenesis.165 Additionally, CAFs trigger angiogenesis either through direct recruitment of 
endothelial precursor cells via chemokine CXCL12, or by recruiting myeloid cells such as 
macrophages or neutrophils that produce proangiogenic factors.166 Additional tumorigenic 
activities of CAFs are under investigation. 
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3.1.2 Endothelial cells in tumor microenvironment 
Endothelial cells form tumor-associated vasculature which is required for nutrients and 
oxygen supply as well as disposal of metabolic waste.167 VEGF, produced by tumor cells or 
CAFs within the tumor microenvironment, is a potent endothelial cell-specific mitogen and is 
crucial for tumor neovascularization. The angiogenic activity attributed to VEGF is, at least in 
part, based on its ability to induce apoptosis regulator protein Bcl-2 in endothelial cells.168 
Indeed, tumor-associated endothelial cells express high levels of Bcl-2.169 Bcl-2 ensures 
enhanced endothelial cell survival and triggers secretion of chemokine CXCL1 and CXCL8 
that in turn mediate signals promoting tumor angiogenesis and growth in head and neck 
squamous cell carcinomas. Further, the chemotactic gradient originating from endothelial 
cells is responsible for CXCR2-dependent tumor cell invasion.170 Besides chemokines, 
endothelial cells secrete various factors including matrix metalloproteases (MMPs) and 
urokinase plaminogen activator (uPA) thereby supporting tumor growth and invasiveness. In 
addition, endothelial cells control the permeability of blood vessels and influence the egress 
of plasma proteins and cells that both directly and indirectly stimulate angiogenesis and other 
aspects of cancer.171 
 
3.1.3 Functions of infiltrating leukocytes in tumor microenvironment 
Bone marrow-derived cells make up a substantial proportion of cells within the tumor 
microenvironment. Different cell populations comprising T and B lymphocytes, mast cells, 
natural killer cells, dendritic cells, monocytes, granulocytes and partially differentiated 
myeloid progenitors have critical modulatory functions during both tumor development and 
metastasis.12,172,173 Inflammatory cells within a tumor can incorporate both tumor-promoting 
as well as tumor killing subclasses. Since cancer progression positively correlates with 
inflammation, it is necessary to understand the complex interplay between tumor and 
inflammatory cells in order to obtain detailed insights into the nature of cancer. 
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In the following sections the importance of myeloid-derived suppressor cells, tumor-
associated neutrophils and tumor-associated macrophages in the tumor microenvironment 
will be discussed in more detail. 
 
3.1.3.1 Myeloid-derived suppressor cells 
Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of cells 
that comprises myeloid progenitor cells, immature macrophages, immature granulocytes and 
immature dendritic cells.174 MDSCs are excessively found in tumors where they accomplish 
different functions. The important function of MDSCs within the tumor microenvironment is 
their immunosuppressive activity.174,175 MDSCs have been shown to suppress T cell 
functions by different mechanisms. For instance, high production of arginase 1 and inducible 
nitric oxide synthase (iNOS) enables MDSCs to inhibit major histocompatibility complex class 
II (MHC-II) expression and to induce apoptosis in T cells.174,176,177 Further, MDSCs promote 
tumor angiogenesis.174,178 They may trans-differentiate into endothelial-like cells and support 
blood vessel formation.179 Elevated levels of signal transducer and activator of transcription 3 
(STAT3) detected in MDSCs trigger the up-regulation of angiogenic genes like VEGF, basic 
fibroblast growth factor (bFGF) and MMPs.180 Abrogation of STAT3 led to diminished MDSC-
mediated angiogenesis. In addition, enhanced expression of MMP9 by MDSCs triggered the 
release of VEGF from the extracellular matrix stimulating the proliferation of endothelial 
cells.181 Finally, in certain cellular contexts, MDSCs can differentiate into mature neutrophils 
or to mature macrophages and exert cell specific functions.182 
 
3.1.3.2 Tumor-associated neutrophils 
Tumor-associated neutrophils (TANs) have been detected in almost all tumors while their 
abundance varies depending on the type and size of a tumor. Several chemotactic factors 
such as CXCL1, CXCL2, CXCL5, granulocyte colony-stimulating factor (G-CSF) or 
granulocyte-macrophage colony-stimulating factor (GM-CSF) are secreted by both tumor and 
stromal cells and contribute to recruitment of neutrophils.183,184 TANs in the tumor 
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microenvironment are activated and polarized either toward an N1 or N2 phenotype 
depending on the cytokine composition. An N1 phenotype is characterized by its antitumor 
activities such as high cytotoxicity and high expression levels of proinflammatory cytokines. 
The ability to mobilize and to activate CD8+ T cells enhances the antitumor activities of N1 
polarized neutrophils.185 In contrast, N2 polarized neutrophils exert protumor activities due to 
a reduced cytotoxicity and increased secretion of immunosuppressive cytokines like IL6 and 
CCL17. Additionally, TANs in an N2 state release growth stimulating factors (e.g. VEGF, IL8, 
CCL2, CCL5) and matrix degrading proteases (e.g. MMP8, MMP9, elastase) that increase 
tumor cell survival and invasiveness.185,186 Finally, N2 TANs have been shown to activate 
tumor angiogenesis by triggering the migration and proliferation of endothelial cells through 
the production of VEGF.187 The depletion of neutrophils with anti-Gr1 antibody at the early 
stage of pancreatic islet tumorigenesis led to a reduced incidence of the “angiogenic switch”, 
demonstrating that neutrophils can switch on angiogenesis.188 Interferon β (IFNβ) 
significantly shapes the ability of neutrophils to mediate angiogenesis. 189 The lack of IFNβ 
led to increased growth of melanoma and fibrosarcoma tumors which were associated with 
high levels of infiltrated neutrophils and enhanced blood vessel formation. Thus, IFNβ 
apparently primes the N1 phenotype, whereas the lack of IFNβ leads to generation of N2 
TANs. In addition, the immunosuppressive cytokine TGFβ has an opposite effect on the 
plasticity of TANs.185 The presence of TGFβ induces N2 polarization, while the absence of 
TGFβ leads to increased recruitment of neutrophils with higher cytotoxicity and production of 
proinflammatory cytokines typical for the N1 phenotype.190 Indeed, in many tumors TANs 
have been shown to manifest N2 behavior that facilitates immunosuppression and tumor 
development. Collectively, these data provide conclusive evidence that tumor 
microenvironment educates TANs and shapes them with properties beyond their classical 
role. 
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3.1.3.3 Tumor-associated macrophages 
Tumor-associated macrophages (TAMs) represent another dominant group of cells that 
populate primary tumors. Similar to neutrophils, circulating monocytes infiltrate tumors in 
response to high concentration of chemotactic factors such as CCL2, CCL5, macrophage 
colony-stimulating factor (M-CSF), VEGF and platelet-derived growth factor (PDGF).144 
Following tumor infiltration, monocytes differentiate into TAMs. Depending on the 
intratumoral composition of the inflammatory stimuli, TAMs may differentiate into M1 
(classical) or M2 (alternative) phenotypes. Analogous to N1 and N2 neutrophils, M1 and M2 
macrophages have opposing functions. IFNγ triggers M1 polarization of macrophages which 
secrete high levels of proinflammatory cytokines (TNFα, IL1, IL6, IL-12, IL23), MHC 
molecules and toxic intermediates such as nitric oxides and reactive oxygen species (ROS). 
Given these properties, M1 macrophages prime an antitumor immune response. Conversely, 
M2 macrophages shape a tumorigenic microenvironment by increased levels of anti-
inflammatory cytokine IL10 and low levels of IL12. In addition, M2 macrophages create an 
attractive immunosuppressed environment for tumor growth by producing arginase, 
TGFand down-regulating the expression of MHC-II molecules. TAMs also represent an 
additional source of VEGF and other angiogenic factors like MMP9 and FGF which facilitate 
tumor angiogenesis.179,191 M2 secreted MMPs, together with other proteolytic enzymes such 
as proteases and heparanases, degrade extracellular matrix and support tumor cell invasion 
and metastasis.145,179,192-194 Moreover, stimulated macrophages release various chemokines 
that amplify and sustain pro-tumorigenic functions.195 
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Figure 5: Protumorigenic functions of TAMs (Sica et al. 2006). 
 
In the majority of investigated tumors, TAMs displayed an M2-like phenotype.196 How the 
balance between tumor-suppressing and tumor-promoting activities of macrophages within 
the tumor is regulated is not completely understood. Tumor cells apply different mechanisms 
to educate TAMs toward a tumor-promoting state.197,198 Anti-inflammatory molecules: IL10, 
IL4, IL13 and glucocorticoid hormones serve as important modulators of the M2 
phenotype.197 Intratumoral IL4 stimulates macrophages to produce high levels of cathepsins 
that are critical for promoting pancreatic tumor growth, angiogenesis, and invasion in vivo.199 
The function of TAMs in the tumor microenvironment is shaped both by tumor cells and other 
stromal cells (e.g. CAFs).197,198 Recently, CD4+ T cells were shown to cause M2 activation via 
IL-4 in a primary mammary carcinoma model.200 Furthermore, the colony-stimulating factor 
(CSF-1)/EGF paracrine loop has been implicated as a possible mechanism of macrophage-
mediated tumor cell invasion.201,202 CSF-1 expressed by tumor cells promoted EGF secretion 
by macrophages. EGF, in turn, stimulated the formation of elongated protrusions in tumor 
cells leading to increased motility and invasion. Interference with the CSF-1/EGF paracrine 
loop resulted in reduced tumor cell invasiveness and showed antitumor effects in vivo.203,204 
Macrophage assistance during tumor cell invasion was confirmed by intravital imaging as 
direct interactions between macrophages and tumor cells were visualized in the invasive 
regions of the tumor.205 
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Characterization of intrinsic pathways responsible for TAM polarization are essential for 
understanding how these cells affect tumor progression.142 Interestingly, the prominent 
transcription factors such as STAT3, STAT6, NF-κB and hypoxia inducible factor α (HIFα) 
have been identified as key orchestrators of M2 polarization.206-209 Since TAMs preferentially 
accumulate in hypoxic areas, up-regulation of HIFα levels have been detected.179 HIFα 
controls the production of angiogenic factors like VEGF, bFGF and chemokines such as 
CXCL8 and CXCL12, thereby promoting tumor progression and continuous recruitment of 
myeloid cells.210,211 Consequently, ablation of HIFα diminished macrophage motility and 
cytotoxic activity under hypoxic conditions.210 Taken together, these data demonstrate the 
impact of hypoxia on the recruitment and polarization of TAMs and highlight the contribution 
of the microenvironment to tumor progression. 
 
3.2. Tumor microenvironment at the metastatic site 
The dynamic interactions of tumor cells with cells in their environment occur not only in the 
primary tumor, but also during circulation in the blood stream and at distant sites of 
metastatic growth.2,12 Following entry into circulation, disseminating tumor cells encounter a 
foreign microenvironment in the blood system and later at the distant site. Besides the 
appropriate genetic or epigenetic alterations that provide tumor cells with specific cues for 
survival, tumor cells apply different mechanisms to adapt and exploit cells in their vicinity. 
These mechanisms determine tumor cell survival and contribute to successful organ 
colonization.2,9 For instance, tumor cells induce the up-regulation of vascular cell-adhesion 
molecules like selectins and integrins in order to identify and bind to vascular beds at 
secondary sites.212,213 Tumor-mediated local activation of endothelial cells triggers the 
expression of inflammatory mediators which facilitate tumor cell extravasation and 
outgrowth.146 Increased production of CCL5 by tumor-stimulated endothelial cells has been 
shown to recruit monocytes to metastatic sites.35 Activated monocytes at metastatic sites 
secrete various factors like MMPs and caspases which facilitate the establishment of 
micrometastases.12 Accumulating data implicate soluble factors produced by primary tumors 
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as mediators of molecular and physiological changes in distant organs that may direct the 
dissemination of malignant cells to the prepared metastatic sites = “metastatic niche”.214-216 
 
3.2.1 Formation of the premetastatic niche 
The existence of so called “premetastatic niches” has been described recently. Premetastatic 
niche is defined as the formation of a fertile environment at a distant site prior to the arrival of 
metastatic cancer cells.217 VEGFR-1-expressing hematopoietic progenitor cells home to 
distinct sites and form receptive clusters that attract metastatic tumor cells.214 These clusters 
not only have a growth-supporting function but also affect the metastatic tropism of the 
primary tumor. Primary tumors release high levels of VEGF into the circulation and recruit 
vascular endothelial growth factor receptor 1 (VEGFR-1) positive hematopoietic progenitor 
cells to the premetastatic niche. The VEGFR-1 function-blocking antibody inhibited formation 
of these clusters and prevented tumor metastasis.214 Other studies revealed additional 
mechanisms that shape the premetastatic niche. Increased fibronectin expression by 
resident fibroblasts caused by tumor-specific growth factors allows very late antigen-4 (VLA-
4)+/VEGFR-1+ hematopoietic progenitor cells to adhere. In response to fibronectin binding, 
activated VEGFR-1+ cells enhance metalloproteinase expression and create permissive 
surroundings for incoming tumor cells.214,218,219 Factors released from the primary tumor such 
as VEGF-A, TNFα and TGFβ induce enhanced production of inflammatory chemoattractants 
S100A8 and S100A9 that cause infiltration of leukocytes to the premetastatic lung.215 Lysyl 
oxidase (LOX) secreted by hypoxic breast tumor has also been shown to accumulate in the 
premetastatic niche.216 LOX is responsible for cross-linking collagen IV, thereby increasing 
the adhesion and accumulation of BMDCs at the site of future metastases.216 In addition, 
stromal-derived factor-1 (SDF-1) is highly up-regulated in premetastatic clusters, and directs 
CXCR-4 expressing tumor cells and BMDCs to sites of metastasis.220,221 Recently, tumor-
derived exosomes have been shown to promote metastatic niche formation.222 Exosomes 
are small membrane vesicles that mediate local and systemic cell communication by 
transferring their contents, including RNAs and proteins, to the cells they fuse with.223 
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Exosomes play an important role in mobilization of BMDCs and their reprogramming towards 
a pro-metastatic phenotype.222 Of note, G-CSF functions as an alternative key initiator and 
regulator of metastatic niche formation.224 Tumor-derived G-CSF stimulated the accumulation 
of Ly6G+Ly6C+ granulocytes in premetastatic tissue and enhanced the homing of breast 
tumor cells to lung.224 These data indicate that primary tumors release several factors 
required for premetastatic niche formation, which probably consists of different cell 
populations of hematopoietic origin. 
The significance of reciprocal interplay between host and tumor cells in tumor cell survival, 
proliferation and metastasis offers new approaches in anti-cancer therapy. Redirection of 
tumor-associated host cells toward tumor destruction represents one possible strategy. 
Although recent experimental studies provide positive results, the “re-programming” remains 
a difficult undertaking.208,225 Since cellular composition and a variety of soluble factors 
determine the activation status of immune cells, further investigations are needed to 
understand the entire complexity of polarization mechanisms.  
Another promising strategy aims to target extracellular mediators that act at the tumor-host 
communication interface.226 Both tumor and host cells secrete a myriad of factors that 
promote tumor cell proliferation, migration, survival and extravasation. Clinical observations 
and animal studies demonstrate that dysregulation of chemokines and chemokine receptors 
enhances tumor development and progression, suggesting their role as prominent 
modulators of the tumor microenvironment.141,195,227,228 Thus, chemokines and chemokine 
receptors might serve as potent target molecules in cancer therapy. 
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4. Chemokines 
Chemotactic cytokines, also known as chemokines, are subdivided into 4 groups: CC, CXC, 
C and CX3C, according to the position of two highly conserved N-terminal cysteines.229 
Owing to their ability to regulate the migration of leukocytes, chemokines are involved in 
embryogenesis, organogenesis, tissue homeostasis and inflammation.230 Alterations in 
chemokine expression have been associated with pathological conditions as shown in 
autoimmune disorders and infectious diseases like HIV or HCV.231 In the last decade a great 
interest in chemokines has emerged as the novel role of chemokines in regulating various 
aspects of cancer has been demonstrated. The effects of chemokines in cancer progression 
are very complex and depend on their cell-specific origin and the appropriate 
microenvironment. 
Many tumor cells aberrantly express chemokines. Chemokines can directly stimulate 
chemokine-receptor expressing tumor cells in an auto/paracrine manner (Figure 6). For 
example, overexpression of CXCL1 in normal melanoma cells accelerated cell proliferation in 
vitro and triggered tumor formation in vivo.232 Along the same line, CXCL8 serves as a 
growth factor in pancreatic and head and neck carcinomas.227,233 Beside the direct beneficial 
effects on tumor cells, angiogenic properties have been attributed to chemokines. CXCL5 
and CXCL8 have been shown to act as pro-angiogenic factors, whereas CXCL9 und 
CXCL10 inhibited angiogenesis. 
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Figure 6: Direct and indirect effects of chemokines on tumor cells. 
Tumor cell-derived chemokines (e.g. CXCL12) promote in a paracrine fashion tumor cell survival and 
proliferation. In addition, local chemokine gradient produced by tumor cells and stromal cells (CCL2, 
CCL5, CCL17, CCL22) triggers the recruitment of inflammatory monocytes and lymphocytes. This in 
turn facilitates tumor progression through the induction of angiogenesis, matrix remodeling and 
immune evasion. Chemokine receptors on tumor cells mediate their dissemination to distant organs 
(Allavena et al., 2011). 
 
Chemokines not only influence local cells, but are also able to induce infiltration of leukocytes 
into the tumor. Up-regulation of CCL5 in a murine model of breast cancer, as well as in 
patients with breast and cervical cancer, was associated with enhanced infiltration of 
monocytes and increased metastasis, respectively.234,235 In a different study, high levels of 
CCL20 in breast carcinomas led to strong infiltration of immature dendritic cells that 
correlated with poor clinical outcome.236,237 Hence, the local production of various 
chemokines determines the amount and the composition of leukocytes in the tumor 
microenvironment. 
Infiltrated leukocytes further amplify the inflammatory response by releasing pro-
inflammatory cytokines, chemokines, growth factors and proteases, thereby promoting tumor 
development and metastasis. Among other properties that were summarized in section 3.1.3, 
TAMs, for instance, produce CCL18 that promotes lung and liver metastasis of breast cancer 
cells via integrin clustering, and enhanced adherence of metastasizing tumor cells to the 
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extracellular matrix.238 Additionally, chemokines not only recruit inflammatory cells, but also 
may change the turnover and plasticity of these cells, thereby sustaining a tumor favoring 
microenvironment.239 
Chemokines exert their pivotal functions through binding to corresponding G-protein-coupled 
receptors displayed on target cells. Proper signaling leads to intracellular calcium 
mobilization and chemotaxis.228 Therefore, tight regulation of chemokine receptors on 
leukocytes is required to assure the trafficking and the retention of leukocytes in tumors. On 
the other hand, a particular repertoire of chemokine receptors on tumor cells may explain the 
tissue tropism typical for some tumor cell lines. For example, tissues with high SDF-1 
expression such as bone, lungs and liver are favorable targets for metastasis of CXCR-4 
expressing breast tumor cells.220 The blockage of CXCR-4 signaling with neutralizing 
antibody abolished metastasis to these organs, indicating the chemokine-chemokine 
receptor axis as a critical factor for metastatic spread. In addition, inhibition of the chemokine 
receptor CXCR3 prevented lung metastasis in a murine model of metastatic breast cancer.240 
This indicates that various chemokine receptors may operate in parallel in order to promote 
cancer progression and metastasis. 
 
Taken together, these data highlight the relevance of individual chemokines as well as 
chemokine-mediated local and systemic signaling in regulating tumor development and 
metastasis. Recently, CCL2 has been identified as a prominent regulator of metastasis.241-243 
CCL2 is produced by many cells like macrophages, fibroblasts, endothelial cells as well as 
tumor cells.244 The mechanisms by which CCL2 promote metastasis are just beginning to be 
understood. In this context, the following section summarizes current findings on the impact 
of CCL2 in metastasis. 
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4.1 CCL2-CCR2 axis in tumor progression 
High levels of CCL2 have been detected in tumors from colon, breast, liver, cervix and 
prostate cancer patients.245-248 Overexpression of CCL2 in tumors correlates with metastasis 
and poor prognosis, indicating the importance of this chemokine in metastatic progression. 
Similarly, up-regulation of CCL2 in prostate cancer cells promoted tumor growth and bone 
metastasis due to increased recruitment of macrophages.242 Another study showed that 
CCL2-mediated recruitment of monocytes facilitated breast cancer metastasis to the lung.243 
CCL2 blockage with neutralizing antibody was associated with reduced macrophage 
recruitment and reduced prostate tumor volume.249 Attenuated metastasis and significantly 
prolonged survival was also observed in breast tumor-bearing mice after treatment with 
CCL2 neutralizing antibody.243 Furthermore, nanoparticle-based silencing of CCR2 in 
monocytes was comparable with the effect caused by CCL2 neutralization and led to 
decreased macrophage recruitment in colorectal and lymphoma tumors.250 Reduced 
lymphoma tumor volume was accompanied by low levels of VEGF and decreased vessel 
density.250 Indeed, CCL2 has been shown to mediate angiogenesis of endothelial cells by 
enhancing the local concentration of VEGF released from recruited monocytes.249 Further 
study demonstrated that CCL2 induced the formation of blood vessels in chick chorioallantoic 
membrane, indicating that CCL2 might directly stimulate vascularization through CCR2 
signaling on the endothelial cells.251 Recently, CCL2 activity has been linked to versican-
mediated lung metastasis in bladder cancer.252 High levels of versican potentiate metastasis 
in patients with bladder cancer and correlations between versican and CCL2 expression 
were detected in metastatic cohorts of human bladder tumors. Interestingly, metastasis 
suppressor molecule RhoGDI2 reduced versican expression and CCL2 secretion thereby 
diminishing macrophage recruitment to the lungs.252 In addition, ablation of CCL2 or CCR2 
attenuated lung colonization of highly metastatic versican-over-expressing bladder cancer 
cells. These data clearly indicate that the premetastatic effect of versican in bladder cancer is 
CCL2/CCR2 dependent. Further, macrophage depletion with clodronate liposomes 
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prevented versican-driven lung metastasis, suggesting that CCL2 function in versican-
mediated lung metastasis is linked to macrophage infiltration. 
Taken together, these data state the role of CCL2 as a facilitator of metastasis functioning 
through the recruitment of monocytes to tumor cells. However, the exact mechanism 
underlying CCL2 signaling during metastasis remains to be elucidated. The effect of CCL2 
on other cells besides monocytes, awaits further characterization. 
 
5. Scientific aims 
5.1 Role of endogenous selectin ligands in metastasis 
Metastasizing tumor cells exploit the immune system for successful colonization. Selectin 
ligands expressed by tumor cells have been shown to promote metastasis through selectin-
mediated interactions with leukocytes.32,136 In the current study, we aim to determine whether 
endogenous selectin ligands are also able to promote metastasis and to understand the 
molecular mechanism underlying this process. Insights into endogenous selectin ligand-
mediated interactions may provide new strategies for preventing or controlling lung 
metastasis. 
 
5.2 Impact of CCL2 on metastasis 
High levels of CCL2 in tumors correlates with high metastatic potential in patients with 
prostate, lung and breast cancer. Recent studies associate the CCL2 metastasis promoting 
effect with the attraction of monocytes/macrophages to the tumor microenvironment. In the 
present study, we aim to analyze the role of CCL2-CCR2 axis in a murine metastatic model. 
Understanding CCL2-CCR2 signaling could help to develop new drugs and target metastasis 
at an early stage. 
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Abstract 
Tumor cell-derived selectin ligands mediate contact to the endothelium, platelets, and 
leukocytes through binding to selectins that facilitates metastasis. Here we describe 
the mechanism how endogenous (non-tumor derived) selectin ligands contribute to 
metastasis using Fucosyltransferase-7 (Fuc-TVII-/-) deficient mice. Experimental 
metastasis of MC-38GFP and 3LL carcinoma cells was attenuated in Fuc-TVII-/- mice 
which express minimal amount of selectin ligands. We show that metastasis is 
dependent on selectin ligands carried on hematopoietic cells. Reduced recruitment of 
monocytes to metastasizing tumor cells in Fuc-TVII-/- mice correlated with attenuated 
metastasis. Adoptive transfer of Fuc-T7+ monocytes rescued metastasis in Fuc-TVII-/- 
mice indicating that selectin ligand-dependent recruitment of monocytes is required 
for successful metastasis. Cytokine analysis in metastatic lungs revealed high 
expression of CCL2 in C57BL/6 mice that was significantly lower in Fuc-TVII-/- mice. 
The absence of monocyte recruitment in Fuc-TVII-/- mice correlated with increased 
apoptosis of tumor cells. Thus, the recruitment of monocytes to metastasizing tumor 
cells is facilitated by endogenous selectin ligands carried by monocytes that enable 
efficient tumor cell extravasation and metastasis. 
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Introduction 
During hematogenous metastasis circulating tumor cells interact with blood 
constituents (platelets and leukocytes), which modulate their capacity to adhere to 
endothelium and to leave blood circulation. Malignant transformation is associated 
with alteration of cell surface glycosylation and presentation of altered glycan 
structures [1; 2]. Furthermore, the enhanced expression of sialyl-Lewisx (sLex) and/or 
sialyl-Lewisa (sLea) is frequently associated with poor prognosis of carcinoma 
patients due to metastasis [3; 4; 5].  
There is substantial evidence that selectins contribute to metastatic spread through 
mediation of tumor cell interaction within the circulation (reviewed in [1; 6; 7]). 
Selectins is a family of cell adhesion molecules, expressed on activated endothelium 
(E- and P-selectin), leukocytes (L-selectin) and on activated platelets (P-selectin) 
which are involved in different physiological situations ranging from thrombosis, 
inflammation, hemostasis and cancer [1; 8]. In the context of cancer progression, P-
selectin facilitate platelet-tumor cell thrombi formation [9], L-selectin mediates 
leukocyte recruitment [10], and E-and P-selectin are required for adhesion of tumor 
cells to endothelium [11; 12]. The direct involvement of tumor cell-derived selectin 
ligands in metastasis has been shown both in vitro and in vivo [13; 14; 15]. Enzymatic 
removal of selectin ligands, carcinoma mucins, resulted in reduced selectin ligand 
interactions and subsequently attenuation of metastasis [15]. In addition, carcinoma 
mucins alone induced thrombosis that was selectin-dependent and required 
bidirectional signaling between neutrophils and platelets [16]. However, there is 
limited data on the involvement of endogenous (non-tumor derived) selectin ligands 
during cancer development and metastasis. 
Selectins mediate the recruitment of leukocytes to inflammatory sites through binding 
to endogenous selectin ligands, expressed both on leukocytes and in the stromal 
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compartment [17; 18]. The mechanism of leukocyte recruitment, however, is not 
unique for cancer situation and has many parallels with inflammation [8; 19]. 
Leukocyte infiltration and secretion of cytokines contribute to metastasis through the 
recruitment of myeloid-derived cells that promote tumor cell extravasation [20; 21; 
22]. Previously we have shown that leukocyte recruitment to metastatic sites was L-
selectin-dependent [10]. Furthermore, increased L-selectin ligand expression was 
detected in the microenvironment of metastasizing tumor cells, but the identity of 
cells and the nature of the ligands remained unclear. The present study aims to 
elucidate the role of endogenous selectin ligands in metastasis using Fuc-TVII-/- mice 
that is deficient in selectin ligands.  
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Material and Methods 
Mice: Animals were maintained under specific pathogen-free conditions, and 
experiments were approved and conform to the guidelines of the Swiss Animal 
Protection Law, Veterinary Office, Kanton Zurich. C57BL/6 mice were purchased 
from the Jackson Laboratory. Fucosyltransferase 7-deficient mice (Fuc-TVII-/-) in a 
C57BL/6 background were kindly provided by Dr. J.B. Lowe (University of Michigan, 
Ann Arbor, MI) and bred in house. 
Cell culture: Mouse colon carcinoma cell line MC-38 stably expressing GFP (MC-
38GFP) was grown in DMEM medium with 10% FCS [23]. Lewis lung carcinoma cells 
(3LL) were grown in RPMI medium with 10% FCS [24]. 
Quantification of Metastasis: Mice were intravenously (i.v.) injected with MC-
38GFP cells (3 x 105) and euthanized after 28 days. Metastatic foci were counted 
and macroscopic pictures of lungs were taken. 3LL (1.5 x 105) were i.v. injected and 
tumor nodules were counted on day 14. 
Histology and immunohistochemistry: Lungs fixed in 4% paraformaldehyde were 
embedded in paraffin blocks. Lungs sections (2 μm) were stained with 
Hematoxylin/Eosin or various antibodies: Ki67 (Cl. SP6, NeoMarkers), anti-CD3 (Cl. 
SP7, NeoMarkers), anti-F4/80 (Serotec), anti-Ly6G (Becton Dickinson (BD), anti-
B220 (BD). For apoptosis assay anti-Caspase-3 (Cell Signaling) and anti-GFP 
(Fitzgerald Industries Int.) antibodies were used. Staining was performed on a 
NEXES immuno-histochemistry robot (Ventana instruments, Switzerland) using an 
IVIEW DAB Detection Kit (Ventana) or on a Bond MAX (Leica). Images were 
digitalized on Zeiss Mirax Midi Slide Scanner and analyzed with Mirax Viewer 1.12. 
software. 
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Bone marrow reconstitutions: C57BL/6 and Fuc-TVII-/- mice were used for 
generation of bone marrow chimeras. Recipient animals were irradiated with 9 Gy in 
one dose and reconstituted by i.v. injection of 1x107 bone marrow cells (isolated from 
femur and tibia). Reconstitution efficiency was analyzed by the presence of selectin 
ligands in the peripheral blood leukocytes and the amount Ly6G+ cells in the blood 6-
7 weeks after reconstitution. 
Flow cytometry: Mice were heart-perfused with PBS. Lungs were minced and 
digested with 2mg/ml Collagenase D (Roche) and 1mg/ml Collagenase A (Roche) for 
1 h at 37°C. Cells were separated using 40 µm cell strainers. Red blood cells were 
lysed using PharmLyse (BD). Cells were incubated with rat anti-mouse CD16/32 mAb 
(BD) and stained with fluorophore-conjugated antibodies against: CD45, CD11b, 
F4/80, Ly6G, Ly6C, CD19, CD4, CD8 (BD). Anti-CD31-FITC antibody (Invitrogen) 
was used as an internal control for lung digestion. The number of tumor cells (MC-
38GFP) in the lungs was quantified as the amount of GFP+ cells per 20’000 CD31+ 
endothelial cells. Blood samples were treated with PharmLyse (BD) and stained as 
described above. Selectin ligands were detected with mouse selectin-Fc chimeras (L-
, P-, E-selectin; 10 μg/ml) that were pre-complexed with biotinylated goat-anti-human 
antibody (1:100; Sigma-Aldrich). Selectin binding was detected with Streptavidin-
CyChrome (BD). Control samples were incubated with selectin chimera in the 
presence of 10 mM EDTA. Data were acquired on a BD FACSCanto II flow cytometer 
(BD) and analyzed using Flow Jo software (Tree Star). 
Analysis of leukocyte-tumor cell association: Frozen lung sections (8-10 µm) 
prepared from C57BL/6 and Fuc-TVII-/- mice injected with MC-38GFP cells were 
stained with following antibodies: CD11b (BD), Ly6G (BD), F4/80 (AbD Serotec). 
Goat anti-rat-Alexa568 Ab (Invitrogen) was used to visualize signals with a 
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fluorescence microscope. Tumor cells were counted and the percentage of tumor 
cells associated with leukocytes was determined. Images were acquired with a SP2 
confocal microscope (Leica) of a total 5 m in a z-axis and analyzed with Imaris 
Software (Bitplane). 
Real-time-PCR: Total RNA was isolated from PBS-perfused and flash frozen lungs 
or sorted cells (monocytes and granulocytes) from lungs using RNeasy Mini Kit 
(Qiagen). The quantity and quality of the RNA was determined using a Nanodrop 
2000 (Thermo Scientific). Purified RNA was reversely transcribed into single stranded 
cDNA using Omniscript RT Kit (Qiagen) according to the manufacturer`s instructions. 
PCR was performed in CFX-96 thermocycler (Biorad) using a SYBR Green 
JumpStart Taq Ready Mix (Sigma-Aldrich) and primers specific for murine GAPDH, 
CCL2, CCL5, IL1, TNFα, TGFβ. Primers purchased from Microsynth (Switzerland) 
are listed in the supplementary Table S1. Expression levels of target genes were 
normalized to the housekeeping gene GAPDH. Relative changes in gene expression 
were calculated using the 2-ΔΔCt method [25]. 
Isolation of bone marrow monocytes: Bone marrow cell were harvested from 6-8 
week old mice by flushing the long bones with PBS containing 2% FCS and 2.5 mM 
EDTA. Red blood cells were lysed using ammonium chloride solution. Bone marrow 
nucleated cells were pre-enriched using the MACS system. Briefly, cells were stained 
with biotinylated M-CSFR antibody (Cl. AFS98, Biolegend) and incubated with 
streptavidin-conjugated magnetic beads (Miltenyi Biotec). After MACS enrichment, 
cells were stained with Gr-1-PE mAb (Cl. RB6-8C5, eBioscience) and M-CSFR+ cells 
were stained with streptavidin-APC (eBioscience). Bone marrow monocytes were 
sorted as M-CSFR+Gr-1int cells using a FACSAria III cell sorter (BD). 
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Adoptive transfer: Fuc-TVII-/- mice were intravenously injected with 2x105 bone 
marrow monocytes isolated from C57BL/6 or Fuc-TVII-/- mice, 6 h post-tumor cell 
injection (MC-38GFP). Mice were euthanized after 28 days and metastasis was 
quantified as described above.  
Statistical analysis: Statistical analysis was performed with the GraphPad Prism 
software (version 4.0). Data are presented as mean  SEM and were analyzed using 
the two-tailed Student’s t-test. 
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Results 
Endogenous selectin ligands facilitate metastasis 
Selectin ligands are sialylated, fucosylated glycan structures with the core structure 
of sialyl Lewisx (sLex). Fucosyltransferase-7 (Fuc-T7) is the major enzyme finalizing 
the synthesis of endogenous selectin ligands in mice [26; 27]. To assess the role of 
selectin ligands during metastasis, we intravenously (i.v.) injected mouse colon 
carcinoma cells expressing GFP (MC-38GFP) in Fuc-TVII-/- mice and lungs were 
analyzed 28 days later. Significant reduction in the number of metastatic foci was 
observed in Fuc-TVII-/- lungs compared to C57BL/6 lungs (Figure 1A-B). 
Immunohistological examination revealed no obvious differences in composition of 
Ki67+ (proliferating cells), F4/80+ (macrophages/monocytes) and Ly6G+ (neutrophils) 
cells within the tumors between Fuc-TVII-/- and C57BL/6 lungs (Figure 1C). However, 
tumors in Fuc-TVII-/- mice showed an enhanced infiltration of B220+ and CD3+ cells. 
Of note, a higher presence of Ly6G+ cells was found in lung tissues of Fuc-TVII-/- 
mice compared to C57BL/6 mice. The overall reduced size of metastatic lesions 
observed in Fuc-TVII-/- mice might be due to the accumulation of lymphocytes in 
tumors. However the significantly reduced numbers of metastatic nodules in Fuc-
TVII-/- mice indicate the importance of endogenous (non-tumor-derived) selectin 
ligands during metastatic seeding. 
To determine whether other tumor cells metastasize in endogenous selectin ligand-
dependent manner, we injected Lewis lung carcinoma cells (3LL) into Fuc-TVII-/- 
mice. Similar to MC-38GFP cells, 3LL cells formed less metastatic nodules in Fuc-
TVII-/- mice compared to C57BL/6 mice (Figure 1D-E). These data are consistent with 
attenuation of metastasis in the absence of endogenous selectin ligands. Of note, 
immunohistochemical analysis revealed no obvious differences in the composition of 
infiltrating leukocytes within the 3LL tumors compared to MC-38GFP tumors (Figure 
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S1). Taken together, evidence obtained from both tumor models indicates that 
endogenous putative selectin ligands contribute to metastatic dissemination. 
We next tested whether tumor cell seeding to the lungs is dependent on endogenous 
selectin ligands. C57BL/6 and Fuc-TVII-/- mice were terminated at various time points 
after tumor cell injection and perfused lungs were analyzed for the presence of GFP+ 
tumor cells (Figure 1F-G). Similar amount of MC-38GFP cells was observed at 30 
min post-injection (p.i.) in both genotypes (Figure 1G). Reduced tumor cell numbers 
were observed in both mice 14 h and 24 h after the injection; however a more 
pronounced decrease of GFP+ cells was detected in lungs of Fuc-TVII-/- mice. Since 
the initial seeding/retention of tumor cells in the lungs was comparable (30 min) and 
the difference in number of GFP+ tumor cells was detected first 14 h later, we 
hypothesized that endogenous selectin ligands are required for tumor cell survival 
and extravasation.  
 
Selectin ligands on hematopoietic cells promote metastasis 
To determine which selectin ligand-expressing cells promote metastasis, we 
generated bone marrow chimeric mice. Reciprocal reconstitutions 
(C57BL/6→FucTVII-/-; FucTVII-/-→C57BL/6) were performed and circulating CD11b+-
myeloid cells were analyzed for the presence of selectin ligands 5 weeks later (Figure 
2A and S2A-B). We confirmed increased levels of Ly6G+ cells in the circulation of 
chimeric mice FucTVII-/-→C57BL/6 (Figure 2B and S2) that was in line with the 
phenotype of Fuc-TVII-/- mice [27]. Chimeric mice were i.v. with MC-38GFP cells and 
the extent of metastasis was quantified after 28 days (Figure 2C-D). Fuc-TVII-/- mice 
expressing selectin ligands in the hematopoietic compartment (C57BL/6→FucTVII-/-) 
displayed strong metastasis comparable to controls (C57BL/6→C57BL/6). On 
contrary, minimal metastasis was observed in chimeric mice expressing selectin 
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ligands on the radio-resistant stromal compartment (FucTVII-/-→C57BL/6). These 
data demonstrate that selectin ligands on hematopoietic cells contribute to 
metastasis. 
 
Endogenous selectin ligands facilitate monocyte recruitment 
We next tested whether the absence of endogenous selectin ligands affects 
recruitment of leukocytes and thereby metastasis. The number of leukocytes 
recruited to the lungs of C57BL/6 and Fuc-TVII-/- mice injected with MC-38GFP cells 
was quantified 14 h and 24 h p.i. by flow cytometry (Figure 3A and S3). Interestingly, 
significantly higher number of leukocytes (CD45+ cells) was detected in lungs of 
untreated Fuc-TVII-/- mice compared to C57BL/6 mice. The analysis of leukocyte 
subpopulations revealed a 5-fold higher presence of Ly6G+ cells 
(neutrophils/granulocytes) in lungs of naïve Fuc-TVII-/- mice compared to C57BL/6 
mice that was also confirmed by immunohistochemical analysis (Figure 3B). Upon 
tumor cell injection, increase in CD45+ cell infiltration was observed in both 
phenotypes. Of note, there was no change in number of Ly6G+ cells in C57BL/6 mice 
while further increase in Fuc-TVII-/- mice 24 h p.i. was detected. On contrary, a 3-fold 
increase in Ly6Chi cells (inflammatory monocytes) was detected in lungs of C57BL/6 
mice 14 h p.i. (Figure 3A). The numbers of Ly6Chi cells in Fuc-TVII-/- mice remained 
on the same albeit higher level regardless of tumor cell injection. Accordingly, we 
observed significantly higher numbers of F4/80+ (macrophages) cells in C57BL/6 
mice. Of note, the analysis of lymphocytes (CD8+, CD4+ and CD19+ cells) revealed 
no changes upon tumor cell injection in both genotypes, although overall lower 
numbers were detected in Fuc-TVII-/- mice (Figure S3). Taken together, tumor cell-
induced leukocyte infiltration to the lungs is dependent on endogenous selectin 
ligands, the absence of which correlated with a reduced recruitment of Ly6Chi cells. 
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The higher numbers of Ly6G+ cells observed in lungs of Fuc-TVII-/- mice seemed to 
be independent of selectin ligand expression. 
 
The absence of Fuc-T7 changes myeloid cell-tumor cell interactions 
To assess whether overall changes in leukocyte infiltration to the lungs alter tumor 
cell–myeloid cell interactions during metastatic colonization, we analyzed lung 
sections from C57BL/6 and Fuc-TVII-/- mice injected with MC-38GFP cells (Figure 
4A). While the majority of tumor cells were associated with CD11b+ cells in lungs of 
C57BL/6 mice at 14 h p.i., there was minimal contact observed in Fuc-TVII-/- mice. In 
addition, 50% of tumor cells were associated with F4/80+ cells in C57BL/6 mice and 
the number increased at 24 h p.i. (Figure 4B). On contrary, tumor cells were 
minimally associated with F4/80+ cells in Fuc-TVII-/- mice at any time point. Of note, 
despite the generally higher residency of Ly6G+ cells in the lungs of Fuc-TVII-/- mice 
an increase in tumor cell association was observed only at 24 h p.i. (Figure 4B). 
Thus, the presence of endogenous selectin ligands on monocytes is required for the 
efficient recruitment of F4/80+ cells to tumor cells during the initial phase of lung 
metastasis.  
The reduced recruitment of leukocytes to metastasizing tumor cells could be a result 
of missing local expression of vascular selectins. Therefore, we tested the expression 
of P- and E-selectin in the tumor microenvironment in Fuc-TVII-/- mice at 6 h p.i. 
(Figure S4). We observed comparable expression of both P- and E-selectin in the 
vicinity of tumor cells in the lungs of both Fuc-TVII-/- and C57BL/6 mice indicating that 
the absence of endogenous selectin ligands did not interfere with the ability of tumor 
cells to activate the endothelium. 
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Monocytes carrying selectin ligands rescue metastasis in FucTVII-/- mice 
Next we tested whether the injection of monocytes carrying selectin ligands affects 
metastasis. Fuc-TVII-/- mice were administered MC-38GFP cells that were followed 
by single injection of purified monocytes isolated from the bone marrow of C57BL/6 
or Fuc-TVII-/- mice 6 h later. Adoptive transfer of C57BL/6 monocytes restored 
metastasis in Fuc-TVII-/- mice to levels comparable to C57BL/6 mice (Figure 5A-B). 
However, no effect on metastasis was observed after intravenous injection of selectin 
ligand-deficient Fuc-TVII-/- monocytes. These data demonstrate that endogenous 
selectin ligands on monocytes are essential for their recruitment to the lungs and 
therefore sufficient to promote metastasis. 
Inflammatory monocytes are known to support cancer through production of 
cytokines, growth factors and chemokines that affect tumor cell survival, tumor 
growth and metastasis [19]. To check whether reduced monocyte recruitment to 
metastasizing tumor cells observed in Fuc-TVII-/- mice affects the microenvironment, 
we examined cytokines in the lungs of tumor injected mice at 24 h (Figure 5C and 
S5). No significant changes in expression levels of IL1, TNF- and CCL5 were 
observed after tumor cell injection in both genotypes (C57BL/6 and Fuc-TVII-/- mice). 
The analysis of neutrophil-specific chemokines, CXCL1, CXCL2 and CXCL5 showed 
minimal changes in mice of both genotypes (data not shown) indicating that the 
general increase in lung neutrophils observed in Fuc-TVII-/- mice is based on a 
different mechanism. Interestingly, the expression of CCL2 was 6-fold higher in 
C57BL/6 mice 14 h p.i. that remained 2-fold above the basal levels also at 24 h p.i 
(Figure 5C). In comparison, CCL2 expression levels were always reduced in Fuc-
TVII-/- mice albeit some induction after tumor cell injection has been detected. Of 
note, TGFβ expression was slightly decreased in lungs of C57BL/6 mice injected with 
tumor cells 24 h p.i. compared to naïve lungs.  
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It was previously shown that CCL2 promotes tumor cell extravasation through the 
recruitment of monocytic cells [21; 22], and mediate a direct endothelial activation 
resulting in increased vascular permeability [22]. Since we observed reduced CCL2 
expression levels in lungs of Fuc-TVII-/- mice we tested the lungs vascular 
permeability upon tumor cell injection. A comparable vascular leakiness was detected 
in C57BL/6 and Fuc-TVII-/- mice (Figure S6). This observation indicated that the 
induction of vascular permeability is independent of selectin-ligand-mediated 
monocyte recruitment, which is in line with previous data showing that tumor cell-
derived CCL2 is mainly responsible for induction of vascular permeability [22]. Thus, 
lower levels of CCL2 in tumor cell-injected Fuc-TVII-/- mice might be due to reduced 
monocyte recruitment to the lungs. To test the hypothesis we isolated monocytes and 
granulocytes from tumor cell-bearing lungs and analyzed CCL2 expression. 
Monocytes (CD11b+Ly6Chigh) isolated from lungs of Fuc-TVII-/- and C56BL/6 mice 
had comparable levels of CCL2 expression that was about 4-fold higher than in 
circulating monocytes (Figure 5D). This finding indicates that monocytes recruited to 
the lungs express higher levels of CCL2 due to local activation upon tissue infiltration. 
We detected minimal expression of CCL2 in granulocytes 
(CD11b+Ly6GhighLy6Cmedium) from both genotypes indicating that neutrophils do not 
significantly contribute to CCL2 presence in the lungs. This data provided evidence 
that the reduced ability of monocytes to be recruited to the lungs due to the absence 
of selectin ligands resulted in lower CCL2 levels in lungs of Fuc-TVII-/- mice. Finally, 
we analyzed whether reduced monocyte recruitment alters tumor cell survival in 
lungs of Fuc-TVII-/- mice. We observed higher apoptosis of tumor cells in lungs of 
Fuc-TVII-/- mice compared to C57BL/6 mice (Figure 5E-F), indicating that the lack of 
monocyte recruitment and therefore inefficient tumor cell extravasation led to tumor 
cell elimination. 
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Discussion 
Inflammatory leukocytes at primary tumor and metastatic sites provide number of 
cytokines; growth factors and matrix-degrading enzymes thereby shaping the 
protumorigenic microenvironment [19; 28]. High infiltration of myeloid cells and 
inflammatory monocytes is often associated with enhanced tumor cell extravasation 
and malignant outgrowth [20; 22; 29]. Recruitment of myeloid cells to the metastatic 
sites has been shown to be dependent on the chemokine gradient (e.g. CCL2, CCL5) 
and on the capacity of leukocytes to adhere to activated endothelium in an L-selectin-
dependent manner [10; 22; 29]. Previously, we observed enhanced expression of L-
selectin ligands that was temporally and spatially restricted to the vicinity of 
metastatic tumor cells in the lungs [10]. Here we provided evidence that endogenous 
selectin ligands on monocytes are directly responsible for their specific recruitment to 
metastatic sites and contribute to tumor cell extravasation. This finding indicates that 
leukocytes recruitment to metastatic microenvironment is similar to inflammation, 
where the recruitment of leukocytes is also determined by selectin ligands on 
leukocytes [30]. Whether leukocytes bind to vascular selectins (P- and /or E-selectin) 
or through L-selectin of already adherent leukocytes requires further investigations. 
We also tested whether Fuc-T7 deficiency has an effect on the primary tumor growth. 
MC-38GFP cells were injected subcutaneously into the flank of Fuc-TVII-/- and 
C57BL/6 mice. Interestingly, the primary tumor grew faster in Fuc-TVII-/- mice 
compared to C57BL/6 mice (Figure S7). This phenomenon is in line with previous 
findings showing an accelerated growth of primary tumors in selectin deficient mice 
[31]. Thus, endogenous selectin ligands restrict primary tumor growth but potentiate 
metastatic outgrowth at metastatic sites indicating that selectins may have spatially 
and temporally defined diverse functions. While we confirmed that selectin-
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dependent recruitment of monocytes facilitates metastasis, the identity and function 
of leukocytes recruited at primary sites remains to be identified. 
Neutrophils during cancer progression exert dual activities either promoting tumor cell 
growth or contributing to elimination of tumor cells depending on the polarization 
status and cellular context [32; 33]. Neutrophil-melanoma cell interactions promoted 
tumor cell retention within the lungs and contributed to transendothelial migration in 
vitro [32]. While in control mesothelioma tumors neutrophils contributed to cancer 
progression, the blockade of TGF- resulted in recruitment of cytotoxic neutrophils 
leading to elimination of tumor cells [33]. Neutrophilia observed in Fuc-TVII-/- mice 
raised also the question whether neutrophils contribute to attenuated metastasis. 
Since increased association of neutrophils was observed 24 h p.i. in Fuc-TVII-/- mice, 
we depleted Ly6G+ cells using 1A8 antibody 6 h after tumor cell injection (Figure S8). 
After four weeks we observed partial rescue of metastasis in Ly6G-depleted animals, 
suggesting that increased neutrophil-tumor cell association contributes to elimination 
of tumor cells in Fuc-TVII-/- mice. These observations were further corroborated by 
detection of apoptotic tumor cells in lungs of Fuc-TVII-/- mice that was increased 
compared to C57BL/6 mice. Several studies reported that reduced recruitment of 
monocytes to tumor cells resulted in increased neutrophil association [22; 34]. 
Recruitment of monocytes to cancer cells was found to be primarily CCL2-dependent 
[22; 29; 34]. Thus, the ability of monocytes to inhibit neutrophil infiltration has been 
suggested [34]. This plasticity in leukocyte recruitment corresponds with our findings 
where reduced monocyte recruitment was accompanied with decreased CCL2 levels 
and resulted in enhanced neutrophil recruitment in Fuc-TVII-/- mice. However, 
intravenous injection of selectin-ligand-positive monocytes rescued metastasis. This 
finding confirmed the involvement of selectin-mediated recruitment of monocytes in 
metastasis. Thus, transient inhibition of selectin-selectin ligand-mediated interactions 
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reveals a potential intervention strategy to block metastatic dissemination at an early 
stage prior to tumor cell extravasation. 
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Figure Legends 
 
Figure 1. Endogenous selectin ligands facilitate metastasis.  A) Representative 
pictures of metastatic lungs from C57BL/6 (n=12) and Fuc-TVII-/- (n=7) mice 28 days 
p.i. with MC-38GFP cells. B) Quantification of metastatic foci 28 days p.i. C) 
Histological analysis of lungs from C57BL/6 and Fuc-TVII-/-  mice 28 days p.i. with 
MC-38GFP cells. Scale bars are indicated. H&E: Hematoxylin & Eosin, Ki67: 
proliferation marker, F4/80: monocytes and macrophages, Ly6G: neutrophils, B220: 
B-cells, CD3: T cells. The insert in Ly6G+ cells shows magnification at the tissue-
tumor interface at higher magnification. Scale bar = 100 m. D) Macroscopy of lungs 
from C57BL/6 and Fuc-TVII-/- mice 14 days p.i. with Lewis lung carcinoma (3LL) cells. 
E) Quantification of tumor nodules (n = 4-5). F) Gating strategy for the quantification 
of GFP-expressing tumor cells in lung homogenates of C57BL/6 and Fuc-TVII-/- mice 
at various time-points. CD31+ endothelial cells (ECs) were used as an internal 
reference. G) Flow cytometry analysis of MC-38GFP cells in lung homogenates at 
different time points after injection. The amount of tumor cells is normalized to 20’000 
ECs. *, p < 0.05. 
 
Figure 2. Selectin ligands on hematopoietic cells are required for metastasis.  
A) Quantification of selectin ligands on monocytes (Ly6Chi cells) from peripheral 
blood of C57BL/6, FucTVII-/- and chimeric mice: C57BL/6→FucTVII-/- or FucTVII-/-
→C57BL/6 using L-selectin (n = 4). B) Quantification of Ly6G+ cells in the peripheral 
blood of control and chimeric mice (n = 4-5). C) Macroscopy of lungs from chimeric 
mice and D) quantification of tumor nodules in lungs of mice 28 days p.i. with MC-
38GFP cells, respectively (n = 5/6). **, p < 0.01; ***, p < 0.001. 
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Figure 3. Fuc-TVII deficiency alters leukocyte recruitment to the lungs.  A) Flow 
cytometry analysis of leukocytes from lung homogenates of untreated mice 
(C57BL/6, Fuc-TVII-/-) and mice 14 h and 24 h p.i. with MC-38GFP cells (n = 4-6). 
The number of leukocytes (CD45+ cells) was normalized to 1’000 endothelial cells 
(ECs). Ly6G+, Ly6C+ and F4/80+ cells are presented as percentage of CD45+ cells. *, 
p < 0.05; **, p < 0.01; ***, p < 0.001. B) Representative confocal microscopy images 
of Ly6G+ cells (red) in lung sections of untreated C57BL/6 and Fuc-TVII-/- mice. Nuclei 
are stained in blue (DAPI). Scale bar: 50 m. 
 
Figure 4. The absence of endogenous selectin ligands reduces myeloid-tumor 
cell interactions.  A) Quantification of the myeloid cell-tumor cell interactions in 
lungs of C57BL/6 and Fuc-TVII-/- mice at 14 h and 24 h p.i. with MC-38GFP cells by 
confocal microscopy. (n = 3). ***, p < 0.001. B) Representative confocal microscopy 
images of the contact of tumor cells (green) with F4/80+ or Ly6G+ cells (both in red) in 
C57BL/6 and Fuc-TVII-/- lungs at 24 h p.i. Nuclei (blue) are stained with DAPI. Scale 
bar: 10 m. 
 
Figure 5. Selectin ligand-expressing monocytes rescued metastasis in Fuc-
TVII-/- mice.  Adoptive transfer of monocytes (monos) isolated from bone marrow of 
C57BL/6 and Fuc-TVII-/- mice that were intravenously injected into Fuc-TVII-/- mice 6 
h p.i. of MC-38GFP cells. A) Macroscopy of lungs from Fuc-TVII-/- mice that were 
injected with C57BL/6 or Fuc-TVII-/- monocytes 28 days p.i. B) Quantification of tumor 
nodules in lungs at day 28 (n = 7-10). C-D) CCL2 expression in the whole lungs (C) 
and monocytes (Ly6Chigh) isolated from lungs (D) of mice i.v. injected with MC-
38GFP cells after 14 h and 24 h, respectively. Data represents two independent 
experiments. Expression levels were analyzed by real time-PCR and normalized to 
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GAPDH. Purified blood monocytes (Ly6Chigh) from untreated mice were used as 
controls. Data are presented as 2-ΔΔct. E) Caspase 3 stained lungs section of C57Bl/6 
and Fuc-TVII-/- mice 24 h after MC-38GFP injection. Three mouse specimens were 
evaluated. Representative images of Caspase3+ tumor cell in Fuc-TVII-/- mice and 
Caspase3- tumor cells in C57BL/6 lungs are shown. F) Analysis of GFP+ tumor cells 
in lungs of mice in parallel to Caspase 3 staining.  *, p < 0.05, ***, p < 0.001. 
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Table S1. 
Primers  Sequences 5`-3` Fragment size (bp.)  Tm (°C) 
CCL2 TTA ACG CCC CAC TCA CCT GC 121 60 
 TGG GGT CAGCAC AGA CCT CTC  
 
CCL5  TGC TGC TTT GCC TAC CTC 121 60 
  ACA CTT GGC GGT TCC TTC 
 
IL1β TCC AGG ATG AGG ACA TGA GCA C 105  60 
 GAA CGT CAC ACA CCA GCA GGT TA 
 
TNFα CCC TCA CAC TCA GAT CAT CTT CT  61  60 
 GCT ACG ACG TGG GCT ACA G 
 
TGFβ1 GCT GAC CCC CAC TGA TAC GC  170 60 
 GTT TGG GGC TGA TCC CGT TGA 
 
CXCL1 CCG AAG TCA TAG CCA CAC TCA A 128 59 
 GCA GTC TGT CTT CTT TCT CCG TTA 
 
CXCL2 GAG CTT GAG TGT GAC GCC CCC AGG 148 60 
 GTT AGC CTT GCC TTT GTT CAG TAT C 
 
CXCL5 GGT CCA CAG TGC CCT ACG 146 59 
 GCG AGT GCA TTC CGC TTA 
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Supplemental Experimental Procedures 
Detection of selectins: Frozen lung sections (8-10 µm) were prepared from mice i.v. 
injected with MC-38GFP cells as described previously [1], and were stained with mAb 
against murine P- and E-Selectin (BD) followed by goat anti-rat-Alexa568 Ab (Gibco). 
Images were acquired on a SP2 confocal microscope (Leica) of a total of 5 m in a z-
axis and analyzed with Imaris Software (Bitplane). Granulocytes were detected with 
anti-Ly6G Ab (BD) in the lungs of C57BL/6 and Fuc-TVII-/- mice and visualized with 
goat anti-rat-Alexa568 (Gibco). 
 
Vascular Permeability assay: Permeability of the lung microvasculature was 
determined using the Evans blue dye as described previously [2]. Briefly, 24 h after 
tumor cell injection, 2 mg of Evans blue were i.v. injected and mice terminated 30 min 
later. Lungs were perfused with PBS, dissected, photographed and homogenized. 
Evans blue was extracted by incubation with formamide at 60°C for 18 h and the 
amount was measured with a spectrophotometer (absorbance at 620 nm). 
 
Neutrophil depletion: Transient neutrophil depletion was achieved using a single 
intravenous injection of 50 μg rat-anti-Ly6G antibody (Cl. 1A8) in 100 μl HBSS. 
Control animals were injected with 50 μg isotype-control Ab (Cl. 2A3) both obtained 
from BioXCell, NH, U.S.A. MC-38GFP cells were intravenously injected 6 h after 1A8 
or isotype control Ab injection. Mice were euthanized after 28 days and metastasis 
was quantified as described above.  
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DISCUSSION 
The tumor microenvironment modulates the behaviour of cancer cells at both the primary 
and metastatic sites.1 Secretion of cytokines together with the recruitment of monocytes has 
been linked to cancer progression and enhanced metastasis.2-5 
1. Endothelial CCR2 - regulator of tumor cell extravasation 
Chemokine receptors expressed on tumor cells were shown to affect the spread of tumor 
cells to particular organs.2,4 For example, CXCR4+ tumor cells metastasized preferentially to 
organs with high SDF-1 expression like bone, lungs and liver.6 Similarly, CXCR3-mediated 
signaling in cancer cells facilitated lung metastasis in a murine model of metastatic breast 
cancer.7 In another model the recruitment of myeloma cells to the bone marrow was CCR2 
dependent.8 The inhibition of chemokine receptors abolished metastasis to the target organs, 
indicating the chemokine-chemokine receptor axis as a possible explanation for the tissue 
tropism typical of some tumor cell lines.6-8 In addition, enhanced CCR2 expression in 
prostate cancer was associated with tumor metastasis to bone.9 CCR2 knockdown in 
prostate cancer cells diminished cell invasion and proliferation, emphasizing the role of 
chemokine receptors in tumor development.9 
The role of host-derived chemokine receptors in metastasis is under investigation. The 
recruitment of MDSCs into the tumor was shown to depend on CCR2, suggesting a role for 
chemokine receptors in tumor immunosuppression.10 Infiltration of CCR2+ inflammatory 
monocytes into primary tumor correlates with tumor progression and increased metastatic 
spread.11-13 Recently, CXCR2 expression in the endothelial compartment was reported to 
contribute to tumor development and metastasis.14 CXCR2 was shown to mediate tumor 
growth and angiogenesis in a murine model of lung cancer. While spontaneous lung 
metastasis was markedly reduced in CXCR2-/- mice, the mechanism by which CXCR2 
attenuated this process remains unclear.14 
High levels of CCL2 in tumors correlates with tumor progression and metastasis.5,15-17 
Therefore, we examined whether CCR2, a receptor for CCL2, contributes to tumor cell 
extravasation and metastasis, respectively. Upon injection of MC-38GFP and 3LL cells, 
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metastasis was markedly reduced in Ccr2-/- mice. Primary tumor growth was not affected in 
Ccr2-/- mice, arguing against the possibility that the observed reduction in metastasis is the 
result of tumor growth rate.18 Using chimeric, transgenic, and knockout mice, we could 
determine the contribution of the endothelial-derived CCR2 and of the CCR2 expressed on 
hematopoietic cells (discussed later) to metastasis. CCR2 expression restricted to 
endothelial cells (Tie2CCR2/Ccr2-/- mice) partially restored metastasis, highlighting the role 
of stromal CCR2 as a facilitator of metastasis. I could demonstrate in vitro and in vivo, that 
tumor cells were unable to migrate through a CCR2-deficient endothelial barrier. Thus, the 
presence of CCR2 on the endothelium is a crucial factor for tumor cell extravasation. 
Interestingly, the absence of CCR2 on endothelial cells did not affect the transmigration 
ability of monocytes, suggesting that transmigration per se, is not limited due to CCR2 
deficiency. How can endothelial CCR2 regulate tumor cell extravasation? The endothelial 
chemokine receptor CXCR2 has been shown to induce vascular permeability in an LPS-
induced model of inflammation.19 Vascular destabilization in the premetastatic phase is a 
prerequisite for metastasis.20 Indeed, vascular permeability in lungs of C57BL/6 mice was 
increased whereas the vascular integrity in CCR2 deficient lungs remained unchanged after 
tumor cell injection. Similarly, a CCR2-/- endothelial monolayer failed to retract in response to 
tumor cells. Taken together, these data provided evidence that tumor cells stimulate 
endothelial CCR2 to open the endothelial barrier, enabling extravasation of tumor cells. 
Activation of endothelial cells implicates several signaling pathways in the process of 
leukocyte diapedesis during inflammation.21,22 For instance, p38MAPK stimulated neutrophil 
emigration in response to keratinocyte-derived cytokine KC.23 Cytokine signaling through 
JAK1-STAT3 regulated actomyosin contractility in tumor cells and stroma.24 Increased 
activity of ERK and p38MAPK was associated with enhanced transendothelial migration of 
colon cancer cells.25 Since, some of these pathways act downstream of CCR226,27, I tested a 
panel of inhibitors to determine which signaling pathways are involved in CCR2-dependent 
transmigration of tumor cells. Inhibition of JAK2, Stat5 and p38MAPK blocked the 
transmigration of tumor cells, whereas inhibitors for PI3K, Rac and Stat5 did not prevent this 
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process. The absence of phosphorylated JAK2, STAT5 and p38MAPK in lung homogenates 
from MC-38-injected Ccr2-/- mice compared to C57BL/6 mice, confirmed that CCR2 
expression is crucial for activation of these signaling cascades. Furthermore, administration 
of JAK2 and p38MAPK inhibitors led to reduced vascular permeability in C57BL/6 lungs upon 
tumor cell injection. Previously observed increases in vascular permeability due to p38MAPK 
activation are in line with our findings.25 Moreover, blocking of signaling pathways 
downstream of CCR2 significantly reduced metastasis, supporting the notion that endothelial 
CCR2 mediates colon cancer extravasation. This study demonstrates for the first time that a 
stromal chemokine receptor controls metastasis by promoting tumor cell extravasation. 
 
2. Tumor cell-derived CCL2 - inducer of vascular permeability 
High levels of CCL2 have been detected in tumors of colon, breast, liver, cervix and prostate 
cancer patients.5,15-17 Our analysis of primary colon tumors (UICC stages I–IV) confirmed the 
link between CCL2 up-regulation in stage IV colon carcinoma and metastatic capacity. 
Several studies reported distinct CCL2 functions in tumor progression.28 For example, CCL2 
acts on cells within the tumor microenvironment such as endothelial cells and monocytes, 
which in turn, promote tumor development and metastasis.12,29 It has been shown that CCL2 
contributes to angiogenesis.29,30 The CCL2-CCR2 axis has also been shown to facilitate 
metastasis through the recruitment of monocytes.11-13 Inhibition of CCL2-CCR2 signaling 
abolished the recruitment of inflammatory monocytes, attenuated metastasis and prolonged 
the survival of tumor-bearing mice.12 However the source of the CCL2 production within the 
tumor microenvironment remained undefined. 
In order to determine the role of tumor and host-derived CCL2 in the process of CCR2-
dependent tumor cell extravasation, I knocked down CCL2 expression in two different 
syngeneic tumor cells lines (MC-38GFP and 3LL). Silencing of CCL2 in tumor cells blocked 
tumor cell migration and impeded vascular permeability in C57BL/6 mice, indicating the 
essential role of tumor-derived CCL2 in these steps of metastasis. CCL2 deficient tumor cells 
could not form lung metastases, corroborating our findings that CCL2 secreting tumor cells 
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exploit endothelial CCR2 signaling for efficient tumor cell extravasation. Moreover, tumor 
cells with normal CCL2 expression induced similar vascular permeability in Ccl2-/- mice 
compared to C57BL/6 mice, highlighting that tumor cell-derived CCL2 is sufficient for the 
initiation of tumor cell extravasation. However, reduced metastasis in Ccl2-/- mice suggests 
that host-derived CCL2 also contributes to recruitment of inflammatory monocytes and 
thereby metastasis.12 Next, performing co-injection experiments of MC-38GFPCCL2kd/MC-38 
cells we could demonstrate that close contact between CCL2+ tumor cells and CCR2+ 
endothelium is necessary for efficient tumor cell extravasation and metastasis. Thus, we 
identified a novel role for tumor cell-derived chemokines in metastasis which goes beyond 
the attraction of inflammatory cells. 
Interestingly, melanoma cell line B16-BL6 expresses only a little CCL2 and could extravasate 
and metastasize independently of endothelial CCR2 expression. This leaves the question 
open whether different tumor cells exploit other endothelial chemokine receptors for 
extravasation. 
 
3. Tumor cell-derived CCL2 - major attractor for inflammatory monocytes 
In accordance with other studies, we could confirm the significance of CCR2+ expressing 
monocytes in metastasis. Silencing of CCR2 in monocytes led to reduced recruitment of 
monocytes to the primary tumor.31 In our study, CCR2 depletion restricted to monocytes in 
LysMCreCcr2loxP/loxP mice strongly affected monocyte recruitment and interaction with tumor 
cells and consequently reduced metastasis. Moreover, the number of metastases in Ccr2-/-
/C57BL/6 chimeric mice was considerably lower than in C57BL/6 mice, corroborating the role 
of CCR2+ monocytes as facilitators of metastasis. CCR2-expressing monocytes deliver 
molecules like VEGF, MMP9, IL10 and TGFβ that promote tumor cell survival and 
extravasation.32,33 Consistent with this, I observed, that monocytes fostered the migration of 
tumor cells through the endothelial barrier. However, the migration of tumor cells through the 
CCR2 deficient endothelial monolayer was blocked, even during co-incubation with 
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monocytes. This highlights that both, CCR2+ monocytes and CCR2+ endothelial cells are 
needed for efficient tumor cell extravasation. 
Tumor cells devoid of CCL2 failed to recruit and interact with inflammatory monocytes, 
suggesting that tumor cell-derived CCL2 is essential for the retention of CCR2+ monocytes at 
metastatic sites. In agreement with other studies18,34 increased association of neutrophils 
(Ly6G+ cells) with tumor cells in the absence of monocytes was observed in CCR2-/- mice, 
implying that neutrophils might also attenuate metastasis. In addition, the effect of CCR2+ 
MDSCs on metastasis in response to tumor-derived CCL2 cannot be excluded.10 
 
4. Endogenous selectin ligands - facilitators of metastasis 
Inflammatory leukocytes act as powerful tumor promoters by secreting various factors like 
matrix degrading enzymes, growth factors, cytokines and chemokines.1,32 Localized at the 
target site, monocytes exert their pro-tumorigenic functions, enabling tumor cell survival, 
extravasation and growth.32,33 Since leukocyte homing is regulated by concerted action of 
adhesion molecules and chemokines21,22, we next investigated the role of endogenous 
selectin ligands in metastasis. Although selectin ligands expressed on tumor cells are 
commonly recognized to facilitate metastasis35-37, the relevance of endogenous selectin 
ligands expressed on leukocytes and endothelial cells in this process is not known. 
Evidence from our laboratory showed that L-selectin on leukocytes facilitated metastatic 
spread in a murine model of experimental lung metastasis.38 The expression of endogenous 
L-selectin ligands was transiently increased in the vicinity of tumor cells.38 This temporal 
appearance correlated with enhanced tumor load, suggesting that endogenous selectin 
ligands might augment metastasis. In this study we investigate the molecular mechanism by 
which endogenous selectin ligands promote metastasis. 
 
4.1. Endogenous selectin ligands capture monocytes at metastatic sites 
Absence of endogenous selectin ligands attenuated lung metastasis in Fuc-TVII-/- mice. 
Reciprocal bone marrow reconstitution experiments showed that endogenous selectin 
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ligands expressed on hematopoietic but not on stromal cells promote metastasis. This is in 
agreement with data demonstrating that selectin ligands on leukocytes are required for the 
recruitment of leukocytes to the inflammatory site.39 The analysis of leukocyte populations 
associated with tumor cells in the lungs from Fuc-TVII-/- and C57BL/6 mice revealed the 
contribution of monocytes and granulocytes to this process. Inflammatory monocytes 
recruited to metastasizing breast and colon tumor cells assist in tumor cell extravasation and 
metastasis.12,40 Lungs devoid of endogenous selectin ligands displayed reduced recruitment 
and association of monocytes with tumor cells. In parallel, adoptively transferred monocytes 
with intact selectin ligands restored metastasis in Fuc-TVII-/- mice, suggesting that 
endogenous selectin ligands are necessary for the capture of monocytes at the metastatic 
site, and are therefore required for metastasis. 
Tumor cells induce vascular permeability and recruit monocytes in a CCL2-CCR2-dependent 
manner.40 Impaired selectin ligand synthesis had no effect on the ability of tumor cells to 
induce vascular permeability, corroborating our previous findings that tumor cell-derived 
CCL2 suffices for activation of endothelial cells. Activated endothelial cells also secrete 
cytokines and chemokines producing a local gradient to attract circulating monocytes.41 
Thus, a comparable chemotactic gradient can be expected at site of tumor cell arrest in 
C57BL/6 and in Fuc-TVII-/- mice. However, reduced association of tumor cells with 
monocytes provides evidence that monocytes lacking endogenous selectin ligands cannot be 
captured at the metastatic site. Ly6Chi monocytes express high levels of PSGL-1, which is 
the ligand for E-, P- and L-selectin.42 Recruitment of Ly6Chi monocytes to atherosclerotic 
lesions is PSGL-1 dependent. Accordingly, inhibition of PSGL-1 leads to reduced monocyte 
accumulation and smaller atherosclerotic plaques.42 Besides the involvement of Ly6Chi 
monocytes in the development of atherosclerosis, Ly6Chi monocytes were shown to facilitate 
metastasis.12,40 These data support our hypothesis that endogenous selectin ligands are 
important for the capture of inflammatory monocytes at the metastatic site through 
interactions with endothelial E-and/or P-selectins. Another possibility is that inflammatory 
monocytes are recruited to metastatic sites through the process of secondary capture. This 
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process was observed previously in atherosclerotic lesions where neutrophils were 
permanently recruited via already arrested neutrophils on the endothelium.43-45 Secondary 
capture is mediated exclusively by L-selectin.44 Since monocytes express L-selectin and L-
selectin ligands, they could also interact with rolling or adherent neutrophils. Whether 
secondary capture-dependent leukocyte recruitment contributes to metastasis remains to be 
explored. 
 
4.2. Endogenous selectin ligands activate monocytes through outside-in signaling 
The chemokine expression profile of lung homogenates from C57BL/6 and Fuc-TVII-/- mice 
after tumor cell injection revealed reduced CCL2 levels in lungs devoid of endogenous 
selectin ligands. Tumor cells, monocytes, neutrophils and endothelial cells produce 
CCL2.46,47 Similar vascular permeability in Fuc-TVII deficient, tumor cell-bearing lungs, 
indicates that defective selectin ligand synthesis might lead to reduced CCL2 production only 
in the host cells. It is likely that impaired selectin ligand-mediated outside-in signaling affects 
CCL2 production in leukocytes. Selectins trigger signal transduction in both selectin-
expressing and ligand-expressing cells.48-50 Selectin ligand-mediated activation of leukocytes 
has been reported previously.51,52 Adhesion of myeloid cells to platelets via P-selectin-PSGL-
1 interactions induced translational amplification of urokinase plaminogen activator receptor 
(uPAR) in myeloid cells.53 Interaction of monocytes with immobilized P-selectin, induced 
nuclear translocation of NF-kB and led to increased secretion of cytokines like TNFα and 
CCL2.54 Recruitment of inflammatory monocytes and their subsequent capture and activation 
at the metastatic site might explain the up-regulation of CCL2 in C57BL/6 lungs. CCL2 
production by activated monocytes could enhance the local CCL2 gradient and in addition to 
tumor cell-derived CCL2 contribute to the permanent recruitment of inflammatory monocytes 
that are required for efficient tumor cell extravasation. The ability of tumor cells to elevate 
CCL2 expression in host cells has been reported previously. 29 Prostate tumor cells up-
regulated CCL2 expression in osteoblasts (3-fold) and endothelial cells (2-fold) via secretion 
of parathyroid hormone-related protein (PTHrP).29 Metastasizing breast cancer cells triggered 
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an inflammatory stress response in osteoclasts, including production of CCL2.55 However, 
the fact that endogenous selectin ligands might also trigger CCL2 expression at the 
metastatic site is rather novel. 
 
Based on our work we propose the following model describing the involvement of 
endogenous selectin ligands in metastasis (Figure 7). After vascular arrest, CCL2-expressing 
tumor cells produce a local chemokine gradient that is required for the recruitment of CCR2+ 
monocytes. Simultaneously or subsequently, tumor-cells induce vascular permeability via 
endothelial CCR2. Selectin-selectin ligand interactions mediate adhesion of recruited 
monocytes at the metastatic site which, following activation, promote tumor cell extravasation 
and metastasis. 
 
Figure 7: Selectin ligand-mediated capture of monocytes at sites of tumor cell arrest. 
This schematic model illustrates how endogenous selectin ligands expressed on monocytes contribute 
to metastasis. Adhesion of tumor cell emboli to the vasculature triggers the activation of endothelial 
cells and the production of the local CCL2 gradient (step1). CCL2 recruits inflammatory monocytes 
and induces vascular permeability through CCL2-CCR2 signaling (step 2). Selectin ligands expressed 
on monocytes interact with selectins displayed on activated endothelium ensuring the adhesion of 
recruited monocytes at the metastatic site where they promote tumor cell extravasation. The absence 
of endogenous selectin ligands on monocytes prevents their adherence at the site of tumor cell arrest, 
resulting in reduced tumor cell survival and metastasis. In addition, lack of selectin ligands is linked to 
reduced CCL2 production, suggesting that selectin ligand-mediated outside-in signaling triggers 
monocyte activation and provides monocytes with metastasis promoting features. 
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4.3. Neutrophils - additional regulators of metastasis? 
Leukocytosis and high infiltration of neutrophils into the lungs raise the question whether 
neutrophils contribute to attenuated metastasis in Fuc-TVII-/- mice. Neutrophils were shown to 
regulate lung metastasis through interaction with, and anchoring of circulating melanoma 
cells to the endothelium.56 Neutrophil-melanoma cell interactions promote tumor cell retention 
within the lung circulation, enhancing extravasation under flow conditions and subsequent 
metastasis development.56 In contrast, in our model, high infiltration of neutrophils did not 
promote metastasis. Instead, high association of tumor cells with neutrophils correlated with 
reduced tumor cell retention within the lung and abolished metastasis. This data indicates 
that different tumor cells use diverse mechanisms and exploit different cell types in their 
microenvironment in order to metastasize. Depending on their polarization status neutrophils 
exert dual activities not only in the primary tumor but apparently also at the metastatic 
site.57,58 
 
Several studies report that reduced recruitment of monocytes goes in hand with increased 
association of tumor cells with neutrophils.18,34,40 Thus, monocytes ability to inhibit neutrophil 
infiltration has been suggested.34 This plasticity in leukocyte recruitment corresponds with our 
findings and explains enhanced neutrophil association in the case of impaired capture of 
monocytes to the metastatic site. Therefore, we hypothesized that tumor cells that are not 
extravasated within 24 hours as a consequence of reduced monocyte capture are 
recognized by neutrophils and are eliminated by acute neutrophil response. Neutrophils 
secrete cytotoxic mediators that have been shown to induce apoptosis and lysis of different 
tumor cells in vitro and in vivo.58 Indeed, increased numbers of apoptotic cells were detected 
in lungs of Fuc-TVII-/- mice compared to C57BL/6 mice 24 hours after tumor cell injection. 
Taken together, these data suggest, that the absence of endogenous selectin ligands results 
in reduced monocyte capture, subsequent neutrophil recruitment, elimination of non-
extravasated tumor cells and reduced metastasis. The phenomenon of observed neutrophil 
recruitment to the lungs within 24 hours is unclear. Based on the 5-fold increase in neutrophil 
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infiltration we can exclude that recruitment of neutrophils occurs in a selectin ligand-
dependent manner. This is in agreement with previous data showing that neutrophils were 
able to infiltrate some organs including lungs by a selectin-selectin ligand independent 
mechanism.59-62 For instance, elevated levels of GM-CSF and IL7 induced granulopoiesis in 
lungs of leukocyte adhesion molecule-deficient mice.63 Another study reported that 
endothelial CXCR2 mediated the migration of polymorphonuclear leukocytes into the lung in 
a murine model of acute lung injury.19 Since mRNA levels of CXCR2 ligands CXCL1, CXCL2 
and CXCL5 were not detectable in lungs of Fuc-TVII-/- mice 24 hours after tumor cell 
injection, the contribution of CXCR2 to neutrophil recruitment in our model is not significant. 
 
Of note, cytokine receptors are frequently glycosylated. It has been reported, that 
fucosylation of the core protein is required for the activation of TGFβ receptor.64 Similarly, 
interaction between chemokine IL-8 and its receptor CXCR2 is fucose-dependent.65 Thus, 
formation of the chemotactic gradient at the metastatic site might be affected due to impaired 
fucosylation of the cytokine receptors that trigger inflammation. Since CCR2 is a 
glycoprotein66, it is also possible that impaired fucosylation of the core protein could influence 
CCR2-mediated outside-in signal transduction. 
 
5. Synopsis and further directions 
This study describes the molecular mechanism of CCL2-mediated metastatic spread. CCL2 
expressing-tumor cells are able to interact with endothelium through the CCR2 receptor 
which leads to increased vascular permeability due to activation of the Jak2 and p38 
pathways. Tumor-derived CCL2 induces the recruitment of CCR2+ monocytes that facilitate 
tumor cell extravasation through the “leaky” endothelium. However, the recruitment of 
monocytes is not sufficient to promote metastasis. Monocytes further require endogenous 
selectin ligands to enable their capture and subsequent activation at the site of tumor cell 
arrest, thus acquiring their pro-metastatic activities. As such, approaches targeting either the 
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CCL2-CCR2 axis or endogenous selectin ligand interactions unveil new strategies in cancer 
therapy. 
 
These findings raise several questions: 
 How exactly are CCL2-mediated events orchestrated during tumor cell extravasation? 
 How can endogenous selectin ligands mediate CCL2 expression? 
 Do other cancer cells also use chemokine-chemokine receptor interactions to 
accomplish tumor cell extravasation? 
 
Consequently, further investigations will provide detailed insights in the role of endogenous 
selectin ligands, chemokines and chemokine receptors in metastasis. 
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